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 Transforming growth factor-β (TGF-β) is a cytokine that plays essential roles in 
regulating embryonic development and tissue homeostasis. In normal cells, TGF-β 
exerts an anti-proliferative effect. TGF-β inhibits cell growth by controlling a cytostatic 
program that includes activation of the cyclin-dependent kinase inhibitors p15Ink4B and 
p21WAF1/Cip1 and repression of c-myc. In contrast to normal cells, many tumors are 
resistant to the anti-proliferative effect of TGF-β. In several types of tumors, particularly 
those of gastrointestinal origin, resistance to the anti-proliferative effect of TGF-β has 
been attributed to TGF-β receptor or Smad mutations. However, these mutations are 
absent from many other types of tumors that are resistant to TGF-β-mediated growth 
inhibition. The transcription factor encoded by the homeobox patterning gene DLX4 is 
overexpressed in a wide range of malignancies. In this study, I demonstrated that DLX4 
blocks the anti-proliferative effect of TGF-β by disabling key transcriptional control 
mechanisms of the TGF-β cytostatic program. Specifically, DLX4 blocked the ability of 
TGF-β to induce expression of p15Ink4B and p21WAF1/Cip1 by directly binding to Smad4 
and to Sp1. Binding of DLX4 to Smad4 prevented Smad4 from forming transcriptional 
 vii 
 
complexes with Smad2 and Smad3, whereas binding of DLX4 to Sp1 inhibited DNA-
binding activity of Sp1. In addition, DLX4 induced expression of c-myc, a repressor of 
p15Ink4B and p21WAF1/Cip1 transcription, independently of TGF-β signaling. The ability of 
DLX4 to counteract key transcriptional control mechanisms of the TGF-β cytostatic 
program could explain in part the resistance of tumors to the anti-proliferative effect of 
TGF-β. This study provides a molecular explanation as to why tumors are resistant to 
the anti-proliferative effect of TGF-β in the absence of mutations in the TGF-β signaling 
pathway. Furthermore, this study also provides insights into how aberrant activation of a 
developmental patterning gene promotes tumor pathogenesis.   
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CHAPTER 1: INTRODUCTION 
 
 
A. TGF-β SIGNALING AND CANCER 
 
Transforming growth factor-β (TGF-β) is a cytokine that controls diverse 
processes such as cell proliferation, differentiation and migration during normal 
embryonic development and in adult tissues (1, 2). TGF-β signaling has a complex 
role in tumors. On one hand, the anti-proliferative effect of TGF-β, which is essential 
for maintaining normal tissue homeostasis, is lost in many cancers. On the other hand, 
the ability of TGF-β to promote cell migration has an important role in tumor metastasis 
(3, 4).  
 
1. The TGF super-family 
 
The TGF super-family is comprised of more than 30 secreted proteins, including TGF-
βs, activins and bone morphogenetic proteins (BMPs). These secreted proteins serve 
as ligands for specific transmembrane type I and type II receptors (3) (Table 1). 
Binding of the ligands to their specific type II receptor activates the corresponding type 
I receptor, which in turn activates specific receptor-activated Smad proteins (R-Smads) 
(Table 1). TGF-β and activin preferably activate Smad2 and Smad3, whereas Smad1, 
Smad5 and Smad8 are selectively activated by BMPs (5). Activation of R-Smads is 
inhibited by specific inhibitory Smad proteins (I-Smads) (i.e. Smad6, Smad7) (6, 7). All 
R-Smads, irrespective of their ligands, associate with a common Smad protein, 
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Table 1. The TGF super-family: Ligands, receptors and signal transducers 
Major TGF ligands, their corresponding receptors and receptor-regulated Smads (R-
Smads) are listed. All R-Smads interact with Smad4 as a common mediator (5, 9, 10). 
 
Ligand Type II receptor Type I receptor R-Smad 
TGF-βs TβRII ALK5 (TβRI) 
Smad2 
Smad3 
Activins 
Nodals 
Lefty 
ActR-II ALK4 (ActR-IB) 
ActR-IIB ALK7 
BMPs 
BMPR-II ALK3 (BMPR-IA) 
Smad1 
Smad5 
Smad8 
ActR-II ALK6 (BMPR-IB) 
ActR-IIB 
ALK2 
MIS MISRII 
? ? ALK1 
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Smad4, to form heteromeric complexes in the nucleus that control transcription of 
distinct sets of genes (8).  
 
1.1. TGF-β signaling pathways 
 
Proteolytic cleavage of latent TGF-β releases a homodimeric complex of two 
polypeptides linked by disulphide bonds (bioactive TGF-β) from latent TGF-β binding 
proteins that tether the ligand in extracellular matrix (11). Binding of active TGF-β to 
the TGF-β type II receptor (TβRII) activates its serine/threonine kinase domain and 
recruits the TGF-β type I receptor (TβRI or ALK5). The TβRII kinase phosphorylates 
TβRI at several serine and threonine residues located within its juxtamembrane 
domain and thereby induces TβRI kinase activity (12). In turn, TβRI kinase 
phosphorylates Smad2 and Smad3 that are tethered to the receptor complex by the 
recruiting protein SARA. Phosphorylated Smad2 and Smad3 translocate into the 
nucleus, where they form heteromeric complexes with Smad4 and other DNA-binding 
factors to activate or repress transcription of distinct sets of genes (9, 12) (Figure 1). 
As discussed in more detail below, this canonical Smad-dependent pathway is crucial 
for mediating the anti-proliferative effect of TGF-β. Induction of cell migration by TGF-
β is also controlled in part by the canonical Smad pathway (Figure 1). TGF-β can also 
trigger signaling pathways that are Smad-independent. Interaction of TβRII and/or 
TβRI with specific adaptor proteins activates distinct signaling pathways such as 
mitogen-activated protein kinases (MAPK), phosphatidylinositol 3-kinase/Akt (PI3-
K/Akt) and Rho GTPases (13-16). These non-Smad signaling pathways are important 
for promoting cell migration in response to TGF-β (17) (Figure 1). 
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Figure 1. The TGF-β signaling pathways 
TGF-β induces activation of Smad and non-Smad signaling pathways. TGF-β-
mediated growth-inhibition is primarily controlled by the canonical Smad pathway. 
TGF-β-mediated cell motility is controlled by both Smad and non-Smad pathways. RII: 
TβRII, RI: TβRI. 
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1.2. Modulation of TGF-β/Smad signaling 
 
The Smad-dependent TGF-β signaling pathway is dynamically modulated at 
multiple levels, from ligand-binding to downstream nuclear events (Figure 2). Binding 
of TGF-β to TβRII is promoted by extracellular matrix proteins such as betaglycan, 
endoglyn and crypto, and is blocked by LAP protein (reviewed in (11)). Stability of the 
TβRI-TβRII complex is down-regulated by Smad7 that acts as an adaptor for the E3 
ubiquitin ligases Smurf1 and Smurf2 (18, 19). Smad7 also prevents recruitment of R-
Smads to TβRI (20). Signaling pathways triggered by various growth factors such as 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and epidermal growth factor 
(EGF) can indirectly inhibit TGF-β signaling by inducing expression of Smad7 
(reviewed in (21)). Nuclear localization and activation of R-Smads are induced by TβRI 
phosphorylation, and are inhibited by phosphatases (22-24). Cytoplasmic retention of 
R-Smads is also caused by extracellular signal-regulated kinase (ERK)-mediated 
phosphorylation (25). TGF-β-induced Smad-dependent transcription is negatively 
modulated by several Smad co-repressors. For example, binding of transforming 
growth interacting factor (TGIF) to Smad2 represses transcription by recruiting histone 
deacetylases (HDACs) to the Smad transcriptional complex (26). Another example is 
the binding of Ski/SnoN to Smad transcriptional complexes that leads to recruitment of 
N-CoR/mSin3/HDAC repressor complexes (27-29).   
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Figure 2. Modulation of TGF-β/Smad signaling  
TGF-β/Smad signaling is modulated at multiple levels from ligand-binding to 
downstream nuclear events. Several key "control-points" are indicated. Red lines 
represent inhibition; blue arrows represent induction.  
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2. Smad-mediated transcription 
 
2.1. Functional domains of Smad proteins 
 
Smad proteins are comprised of two functional domains, Mad homology 1 
(MH1) and Mad homology 2 (MH2), with an intervening linker region (8, 12) (Figure 3). 
MH1 domains contain nuclear localization signal (NLS) sequences and are 
responsible for interacting with Smad-binding DNA elements (SBE). MH2 domains are 
highly conserved between R-Smads. MH2 domains mediate interactions of R-Smads 
with TβRI, with one another, with Smad4, and with other transcription factors (12). 
Phosphorylation of two serine residues at the unique C-terminal Ser-Ser-X-Ser (SSXS) 
motif by TβRI kinase results in nuclear localization and activation of R-Smads (30, 31). 
Conversely, phosphorylation of linker domains by ERKs causes cytoplasmic retention 
of R-Smads. Linker domains are divergent among R-Smads and Smad4. The linker  
region of Smad4 possesses a nuclear export signal (NES) (Figure 3). This NES and 
the NLS signal, located in the MH1 domain, allow Smad4 to shuttle in and out of the 
nucleus (Figure 3).  
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Figure 3. Functional domains of Smad proteins  
MH1 domains of Smad4 and R-Smads contain a nuclear localization signal (NLS).  
Smad4 also contains a nuclear export signal (NES). The MH1 domains mediate DNA 
binding. Smad2 contains an extra 30 amino acids (yellow box) that abrogates its DNA-
binding ability. MH2 domains of R-Smads contain the SSXS motif that is 
phosphorylated by TβRII kinase. Adapted with permission from Wiley‐Liss, Inc: JCB, 
Kimberly et al., copyright 2007 (32) 
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2.2. Smad-mediated transcription regulation 
 
TGF-β induces formation of R-Smad/Smad4 complexes either as hetero-trimers 
(two R-Smads + Smad4) or as hetero-dimers (one R-Smad + Smad4) (33). The 
binding affinity of Smad MH1 domains to SBEs (5’-AGAC-3’) is very low (33). 
However, high DNA-binding affinity and specificity are achieved by interaction of Smad 
hetero-dimers or -trimers with other DNA-binding factor(s) to form large transcriptional 
complexes that either induce or repress specific sets of target genes (8, 34, 35). 
 
Smad-mediated transcription induction 
 
Both the strength and specificity of Smad-induced transcription are governed by 
interactions between activated R-Smads, Smad4, and specific transcriptional 
activators with their corresponding DNA-binding elements on target promoters. A 
classic example is the induction by TGF-β of expression of the cyclin-dependent 
kinase (CDK) inhibitor p15Ink4B. The proximal promoter region of the p15Ink4B gene 
(positions −110/−40) contains two adjacent sets of SBEs and GC boxes that are 
bound by the transcription factor Sp1 (36). TGF-β induces p15Ink4B transcription by 
stimulating cooperative interactions between Sp1 and Smad proteins that enhance 
their DNA-binding and transcriptional activities (Figure 4A). Transcriptional activation 
by TGF-β of the gene encoding the CDK inhibitor p21WAF1/Cip1 is also mediated by 
cooperative interactions between Sp1 and Smads. This is achieved via two distinct 
promoter regions, a distal region (located 1.7 kb upstream of the transcription start 
site) that contain SBEs, and a proximal region (located between positions −124 to −61)  
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Figure 4. Smad-mediated transcriptional activation  
Smads can induce transcription of target genes by [A] recruiting transcriptional 
activators (e.g. Sp1) and/or histone acetylases (e.g. CBP/p300) and by [B] displacing 
transcriptional repressors (e.g. Brk).  
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that have Sp1-binding sites (37, 38). It is thought that coupling of the distal and 
proximal promoter elements and formation of the Smad-Sp1 transcription complex 
occurs via chromatin remodeling (10, 34, 39). Increasing evidence indicates that the 
histone acetyltransferase CBP/p300 is a major co-activator for Smad-mediated 
transcriptional activation (40-43) (Figure 4A). Smads also can activate specific genes 
by displacing transcriptional repressors. For example, binding of MAD (Drosophila 
homolog of R-Smad) to the Dpp (Decapentaplegic) promoter dislodges the Brk 
(Brinker) repressor from the Dpp promoter (44) (Figure 4B).  
 
Smad-mediated transcription repression 
 
Although Smad proteins have intrinsic trans-activating activity, gene repression 
accounts for about one-quarter of TGF-β-mediated gene responses (45). Mounting 
evidence implicates a central role for Smad3, but not Smad2, in TGF-β-mediated 
transcription repression. A well-studied example is TGF-β-mediated repression of c-
myc transcription (Figure 5A).  Smad3 binds to the co-repressor p107 in a complex 
with E2F4/5 and DP1. In response to TGF-β stimulation, this complex translocates into 
the nucleus and interacts with Smad4 via Smad3. Smad4 binds to the SBE, while 
E2F4/5 binds to the E2F binding site. The E2F binding site and the SBE are both 
located within the TGF-β inhibitory element (TIE) of the c-myc promoter. Interaction of 
E2F4/5-DP1-p107-Smad3-Smad4 repressive complex with the TIE element blocks c-
myc transcription (46, 47) (Figure 5A). On the other hand, Id1 transcription is blocked 
by the Smad co-repressor ATF3. ATF3 forms inhibitory complexes with Smad3 and 
Smad4, and ATF3 expression itself is induced by Smads (48). Smad3 also represses 
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Figure 5. Smad-mediated transcriptional repression 
Smads can repress transcription of target genes by [A] recruiting transcriptional 
repressors (e.g. p107), [B] recruiting HDACs (e.g. HDAC4), and [C] sequestering 
transcriptional activators (e.g. MyoD).  
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transcription by recruiting HDACs. Smad3 blocks osteoclacin expression by binding 
Runx2 and recruiting HDAC4 to form a repressive complex that inhibits Runx2-induced 
osteoclacin transcription (49) (Figure 5B). In addition to recruiting repressors, Smad3 
blocks binding of transcriptional activators to target gene promoters. For example, 
Smad3 inhibits transcription of the muscle creatine kinase (MCK) gene by binding 
MyoD and blocking formation of MyoD-E12/47 dimers and their binding to the E-box 
motif (50) (Figure 5C). 
 
3. Cellular responses to TGF-β 
 
3.1. TGF-β-mediated growth inhibition 
 
In most types of normal cells, TGF-β has a potent anti-proliferative effect. TGF-
β primarily inhibits cell growth by inducing cell cycle arrest in G1 phase (3). TGF-β 
controls a cytostatic program of gene responses that includes activation of CDK 
inhibitors and repression of growth-promoting transcription factors (Figure 6). Gene 
responses that are central to this program are induction of p15Ink4B and p21WAF1/Cip1 
(38, 51) and repression of c-myc and inhibitors of differentiation (Ids) (3, 48, 52). Each 
of these gene responses leads to G1 arrest by distinct but integrated mechanisms. 
p15Ink4B forms an inactive complex with CDK4/6 that prevents activation of CDK4/6 by 
cyclin D (53) (Figure 6). Conversely, p21WAF1/Cip1 binds to and inhibits cyclin A/D/E-
CDK2 and cyclin D-CDK4/6 complexes  (54) (Figure 6). E2F family members are 
crucial for G1/S transition and S phase progression (55). Inhibition of CDKs keeps the 
Rb protein in an unphosphorylated and active form such that Rb is able to bind and     
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Figure 6. TGF-β induces cell cycle arrest 
TGF-β induces expression of the CDK inhibitors, p15Ink4B and p21WAF1/Cip1, and inhibits 
expression of c-myc and Id transcription factors. Induction of p15Ink4B and p21WAF1/Cip1 
and down-regulation of c-myc and Ids lead to increased repression by Rb protein of 
the E2F transcription factors that normally promote G1 to S phase progression. Red 
lines represent inhibition; blue arrows represent induction. 
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block transcriptional activity of E2F proteins (56) (Figure 6). On the other hand, c-myc 
induces expression of cdc25A which dephosphorylates and activates Cdk4/6 (57) 
(Figure 6). TGF-β also inhibits expression of Id1, Id2 and Id3 (3, 48, 58). Binding of Id  
proteins to unphosphorylated Rb dislodges Rb from E2F transcription factors, thereby 
releasing E2Fs from the inhibitory effect of Rb (59) (Figure 6). As discussed above 
(section 2), transcriptional activation of p15Ink4B and p21WAF1/Cip1, and repression of c-
myc and Ids occur in a Smad-dependent manner (Figures 4, 5). However, there is 
evidence that TGF-β can also induce G1 arrest by a Smad-independent mechanism. It 
has been reported that TGF-β induces protein phosphatase 2A (PP2A) that 
dephosphorylates and deactivates p70S6K, a kinase that plays a role in G1/S 
progression (60, 61). The TGF-β cytostatic program is tightly integrated by feedback 
loops that protect against competing mitogenic signals. c-myc represses transcription 
of p15Ink4B and p21WAF1/Cip1, but its own transcription is repressed by TGF-β (46, 62, 
63) (Figure 7). TGF-β/Smad signaling inhibits Id2 expression by repressing expression 
of c-myc, an activator of Id2 transcription, and by inducing expression of the c-myc 
antagonist MAD4 (58, 64). 
 
 The role of TGF-β in programmed cell death varies depending on the cell type 
and cellular conditions (65-69). Several genes that are induced in a Smad-dependent 
manner can promote apoptosis. For example, TIEG, an early response gene induced 
by TGF-β, induces apoptosis in pancreatic epithelial cell lines (68). On the other hand, 
activation of several Smad-independent pathways by TGF-β can inhibit apoptosis. 
TGF-β blocks serum withdrawal-induced apoptosis by suppressing JNK activity in lung  
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Figure 7. Integrated control of the TGF-β cytostatic program 
The TGF-β cytostatic program is tightly integrated by feedback loops that protect 
against competing mitogenic signals. For example, c-myc represses transcription of 
p15Ink4B and p21WAF1/Cip1. On the other hand, c-myc transcription is repressed by TGF-
β .  
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carcinoma cells and Akt activity in mammary epithelial cells and skin keratinocytes (65, 
67). However, the program of TGF-β-mediated apoptosis is not well-defined (3) 
 
3.2. TGF-β-induced cell motility 
 
During normal developmental patterning and tissue repair, cells often acquire 
migratory and invasive properties (2). In response to TGF-β, epithelial cells acquire 
fibroblastic morphology and become motile and invasive. The hallmarks of this 
conversion, termed epithelial-to-mesenchymal transition (EMT), are cytoskeletal 
reorganization (actin reorganization, stress fiber formation), junctional disassembly 
(dissolution of tight junctions, adherens junctions and desmosomes) and loss of apical-
basolateral polarity (2, 17).  
 
TGF-β promotes EMT in part by inducing expression of transcription regulators 
that belong to the Snail, ZEB and bHLH families in a Smad-dependent manner (Figure 
8). These transcription factors repress expression of major transmembrane 
components of adherens and tight junctions of epithelial cells, and conversely activate 
expression of mesenchymal genes (2). Snail1 and Snail2 (Slug) repress expression of 
E-cadherin, plakoglobin, claudins and occludin (70-72). Conversely, Snail proteins 
induce expression of vimentin, fibronectin, vitronectin and N-cadherin (73, 74), 
extracellular matrix proteins (collagen type III and V) (73) and regulators of migration 
and invasion (RhoB, plasminogen activator inhibitor-1, matrix metalloproteinase MMP-
9) (74, 75). ZEB1 and ZEB2 (SIP1) repress expression of E-cadherin (76, 77), 
desmosome protein plakophilin-2 and tight junction proteins claudin-4 and ZO-3, and  
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Figure 8. Induction of EMT and cell motility by TGF-β  
TGF-β promotes EMT and cell motility by both Smad-dependent and Smad-
independent (non-Smad) mechanisms. EMT-inducing transcription factors (Snail, ZEB 
and bHLH families) are induced by TGF-β in a Smad-dependent manner. These 
transcription factors repress expression of epithelial genes and activate expression of 
mesenchymal genes. Activation of non-Smad signaling pathways by TGF-β enhances 
cell motility by inducing cytoskeletal reorganization and junctional disassembly. 
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conversely enhance expression of vimentin, N-cadherin and MMP-2 (78). The bHLH 
transcription factor members Twist1 and Twist2 repress expression of E-cadherin, 
occludin and claudin-7, and induce vimentin and N-cadherin (79).  
 
Increasing studies indicate the importance of non-Smad signaling pathways in 
TGF-β-induced EMT (Figure 1). Inhibition of the MAPK, Rho GTPase and PI3-K/Akt 
pathways blocks TGF-β-induced EMT in epithelial cells (13, 80-83). Activation of 
MAPK members is mediated via different TGF-β receptor adaptor proteins. TRAF6 
activates TAK1 which in turn activates p38 MAPK and c-Jun N-terminal Kinase (JNK) 
(84, 85). Shc activates Ras which then activates ERK1 and ERK2 (86). ERK1/2 
indirectly regulate genes that control cell-matrix interactions, cell motility and 
endocytosis (45). Activation of MAPK signaling induces junction disassembly and cell 
motility (reviewed in Ref. (87, 88)). TGF-β induces rapid activation of Rho GTPases. 
Activated RhoA induces p160ROCK (RhoA kinase) (89) which induces stress fiber 
formation and stimulates LIM kinase. Induction of cofilin by LIM kinase causes re-
organization of the actin cytoskeleton (90, 91). Conversely, RhoA activity is controlled 
by Par6 that activates the E3 ubiquitin ligase Smurf1, which in turn controls RhoA 
activity at tight junctions by targeting it for degradation (14). TGF-β induces interaction 
of the regulatory subunit of PI3-K with TβRI receptor resulting in rapid activation of the 
PI3-K/Akt signaling pathway (16). Activation of this signaling leads to reduced cell-cell 
adhesion and the acquisition of spindle cell morphology (13, 92, 93). Akt has been 
reported to repress transcription of E-cadherin (93), induce expression of 
metalloproteinases (94) and induce delocalization of E-cadherin, ZO-1 and integrin-β1 
from cell junctions (13).   
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4. Complex role of TGF-β in tumorigenesis 
 
 Tumorigenesis is a dynamic process characterized by multiple acquired 
capabilities that include insensitivity to anti-growth signals, limitless replicative 
potential, self-sufficiency in growth signals, evasion of apoptosis, sustained 
angiogenesis and tissue invasion (95). TGF-β  plays a complex role in tumorigenesis 
by facilitating the cancer cell's acquisition of these key capabilities (21, 95) (Figure 9).  
 
4.1. Promotion of tumor progression by TGF-β 
 
TGF-β promotes tumor progression by exerting both cell-autonomous and non-
cell-autonomous effects. The cell-autonomous effect of TGF-β is the recapitulation of 
normal TGF-β-induced EMT and is crucial for tumor metastasis (2, 9). Blockade of 
TGF-β signaling inhibits tumor cell invasiveness, whereas restoring TGF-β signaling in 
non-invasive tumor cells promotes invasiveness (96). TGF-β also promotes tumor 
progression by exerting non-cell-autonomous effects on the tumor microenvironment. 
TGF-β promotes tumor angiogenesis in part by inducing expression of angiogenic 
cytokines, and also MMP-2 and MMP-9 that induce endothelial cell migration and 
invasion (97-100). Furthermore, TGF-β causes immunosuppression and enables 
tumor cells to escape from immunosurveillance (101-103). TGF-β represses the 
function of cytotoxic T cells by inhibiting expression of interleukin-2 and its receptors, 
which are crucial for T-cell proliferation (104, 105). TGF-β causes loss of tumor cell 
immunogenicity by repressing expression of major histocompatibility complex antigens  
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Figure 9: Multiple roles of TGF-β in tumorigenesis 
TGF-β signaling has a complex role in tumorigenesis. TGF-β induces migratory 
behavior of normal cells and promotes metastasis of tumor cells. TGF-β also promotes 
tumor angiogenesis and immunosuppression. TGF-β inhibits proliferation, induces 
apoptosis and maintains genomic stability in normal cells. The anti-proliferative effect 
of TGF-β is lost in many cancers.  
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(106-108). TGF-β also inhibits activity of other immune cells such as killer cells, NK 
cells (109), neutrophils (110), macrophages and B cells (102, 111).     
 
4.2. Resistance of tumors to the anti-proliferative effect of TGF-β 
 
A major hallmark of cancer is acquired insensitivity to anti-growth signals (95). 
In many normal cell types, TGF-β has a potent anti-proliferative effect. However, many 
tumors are resistant to the anti-proliferative effect of TGF-β (3, 4, 39). Mutations of 
some core components of the TGF-β signaling pathway such as TβRI, Smad2 and 
Smad3 are rarely found (<5%) in cancers (39, 112). However, resistance to the 
growth-inhibitory effect of TGF-β in some cancers has been attributed to mutations in 
other core components, in particular, TβRII and Smad4 (Table 2). Inactivation of TβRII 
due to somatic mutations has been reported to occur at high frequency (60-90%) in 
colon cancers with microsatellite instability (MSI) (112-114). Mutations or deletions of 
Smad4 have been reported in ~50% of pancreatic and non-MSI colorectal cancers 
(112, 115). TGF-β receptor mutations have been found in 12-31% of ovarian cancers 
(116, 117) but many ovarian cancers that are resistant to TGF-β were reported to 
express functional receptors (118). However, mutations in TβRII and Smad4 are rarely 
found in various other types of cancers such as lung and prostate cancers (112, 119-
121) (Table 2). Similarly, many TGF-β-resistant breast cancers rarely contain TGF-
βRII or Smad mutations (122, 123) (Table 2).  The rareness of mutations in core 
components of the TGF-β signaling pathway in many tumors therefore indicates that 
resistance to TGF-β also stems from other aberrations.  
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Table 2. Mutation frequency of TGF-β signaling components in cancers  
Mutation frequency of TβRII and Smad4 genes in some types of cancers are listed. 
+MSI: Cancer with microsatellite instability, -MSI: Cancer with no microsatellite 
instability. nd: Not detected. Mutations which are rarely detected are indicated as <5%:  
 
Cancer  TβRII Gene  Smad4 Gene  Reference 
Colon  60-90% (+MSI) 50% (-MSI) 
(113-115, 124, 
125) 
Pancreas  4% 50% (125) 
Ovary  12-31% 12% (116, 117)  
Lung  nd (+MSI) 7% (119, 121)  
Prostate  <5% <5% (120)  
Breast  <5% <5% (122, 123) 
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B. ABERRATIONS OF HOMEOBOX GENES IN HUMAN CANCERS  
 
Homeobox genes comprise a large super-family of evolutionarily conserved 
genes that encode transcription factors (126, 127).  Homeobox genes play essential 
roles in controlling developmental patterning (127-130). Many homeobox genes are 
aberrantly expressed in tumors, but the functional significance of their aberrant 
expression is poorly understood (131). 
 
1. Overview of homeobox genes 
 
Transcription factors encoded by homeobox genes are characterized by their 
highly conserved 61 amino acid DNA-binding domain termed the homeodomain. This 
domain forms three alpha helices that bind DNA elements containing a TAAT core 
motif (127) (Figure 10).  The homeobox gene super-family is categorized into several 
different families based on sequence similarities in their homeodomain and other 
functional motifs (132, 133) (Figure 11). Members of the HOX and DLX homeobox 
gene families are organized in clusters. In mammals, the 39 members of the HOX 
family are organized in four clusters located on different chromosomes. The 6 
members of the DLX family are located upstream of these HOX loci (134, 135) (Figure 
12). These HOX-DLX clusters have been postulated to derive from gene duplication 
during evolution (128, 136).  
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Figure 10. Structure of homeodomain proteins 
Transcription factors encoded by homeobox genes contain a conserved homeodomain 
that binds DNA. The homeodomain forms three α-helixes (colored boxes) that bind 
DNA sequences containing a TAAT core motif. Adapted with permission from Nat Rev 
Cancer, Abate-Shen, copyright 2002 (131). 
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Figure 11. Classification of homeobox genes 
The homeobox gene super-family comprises more than 200 genes that are 
categorized into different families. The DLX family comprises six members. 
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Figure 12. Gene clusters of DLX and HOX families 
Members of the mammalian HOX and DLX homeobox gene families are organized in 
clusters. The 39 members of the HOX family are organized in four clusters located on 
different chromosomes. The 6 members of the DLX family are located upstream of 
these HOX loci. Adapted with permission from Springer: Cell, Krumlauf, copyright 
1994 (128). 
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2. Homeobox genes in development and cancer 
 
Homeobox genes play essential roles in controlling cell differentiation, tissue 
morphogenesis and specification of the body plan during embryonic development. 
Distinct sets of homeobox genes control organogenesis, development of the central 
nervous system, limb and skeletal patterning, and craniofacial morphogenesis (137, 
138). Homeobox genes also control cell renewal and tissue regeneration processes in 
adults, including hematopoiesis, spermatogenesis and endometrial remodeling during 
the menstrual cycle (139-143). Aberrant expression of various homeobox genes has 
been reported in different types of tumors (Tables 3, 4). A general trend is that 
homeobox genes that are normally expressed in differentiated adult tissues are down-
regulated in tumors, whereas homeobox genes that are normally expressed in 
embryonic tissues are activated in tumors (131, 144) (Figure 13). This aberrant 
expression of homeobox genes in tumors is thought to reflect an inappropriate 
recapitulation of embryonic pathways (131, 144). Several homeobox genes that are 
down-regulated in tumors have tumor-suppressive functions (144) (Table 3). Loss of 
function of these homeobox genes appears to drive cells back to a less differentiated 
state and promotes cell survival and proliferation (144). Down-regulated expression of 
several homeobox genes in tumors has been attributed to epigenetic mechanisms and 
chromosomal aberrations. For example, loss of HOXA5 expression in breast tumors is 
due to promoter methylation (145). Loss of NKX3.1 and CUTL1 expression in prostate 
and uterine cancers stems from loss of heterozygosity (146, 147). On the other hand, 
aberrant activation of several homeobox genes that are normally expressed in 
embryonic tissues promotes tumor cell proliferation and survival (Table 4). Aberrant 
expression of homeobox genes in leukemias primarily arises from chromosomal    
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Table 3. Examples of homeobox genes that are down-regulated in tumors 
 
Gene  Cancer () Normal expression pattern Functional significance Reference 
CDX2  Colon ()  Expressed in adult intestinal 
epithelium 
Inhibits growth of colon carcinoma 
cells by inducing expression of 
p21WAF1/Cip1. Heterozygous deletion 
increases susceptibility to 
carcinogenesis. 
(149-152) 
NKX3.1 Prostate () Expressed in adult prostate 
epithelium  
Null mutant mice are predisposed to 
prostate cancer. Loss of expression 
correlates with tumor progression.  
(146, 153, 154) 
HOXA5 Breast () Expressed in normal breast 
epithelium. 
Regulate p53 expression .Loss of 
expression was found in 60% of 
breast cancer to be due to promoter 
methylation.   
(145, 155)  
BARX2 Ovary () Expressed in normal adult 
ovarian surface epithelium 
Has tumor suppressive and anti-
metastatic properties. Can modulate 
cisplatin sensitivity. Frequently 
deleted in ovarian cancer 
(156, 157)  
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Table 4. Examples of homeobox genes that are up-regulated in tumors 
 
Gene  Cancer () Normal expression pattern Expression and Function in tumors Reference 
PAX2  Renal () 
 
Expressed during embryonic 
urogenital development but 
not in adult kidney.  
Expressed in renal cell carcinomas. 
Promotes cancer cell survival. 
(158-161) 
HSIX1  Breast ()  Expressed in developing 
eye, brain, muscle, 
embryonic mammary gland.  
Promotes cell cycle progression by 
activating cyclin A1 expression. 
(162, 163) 
GBX2 Prostate () Expressed in developing 
nervous system. 
Induces cell growth by inducing 
expression of interleukin-6. 
(164, 165) 
HOXB7 Melanoma 
Ovarian 
Breast 
 Promotes tumor growth and 
angiogenesis by inducing expression of 
fibroblast growth factor-2. Induces EMT. 
Promotes DNA repair. 
(166-169)  
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Figure 13. Aberrant expression of homeobox genes in tumors 
Homeobox genes that are expressed during embryonic development, but are down-
regulated in normal adult tissues, are often up-regulated in tumors. Conversely, 
homeobox genes that are expressed in normal adult tissues are often down-regulated 
in tumors. Adapted with permission from Nat Rev Cancer, Abate-Shen, copyright 2002 
(131). 
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translocations. Several chimeric oncoproteins arise from fusion of the NUP98 gene 
and HOX genes (144, 148). However, the mechanisms that give rise to activation of 
homeobox genes in solid tumors are largely unknown. 
 
3. Significance of the homeobox gene DLX4 in cancer  
 
Most homeobox genes are expressed in a tissue-specific manner. DLX4, a member of 
the DLX homeobox gene family, is expressed in normal bone marrow cells, 
trophoblast, placenta and endometrium, but is not expressed in most other normal 
adult tissues (170-172). DLX4 has been increasingly reported to be expressed in 
diverse types of tumors (Table 5). The DLX4 gene maps to the 17q21.3-q22 region 
(173, 174). Amplification of this chromosomal hot-spot in breast and ovarian cancers 
correlates with poor prognosis (175). Aberrant expression of DLX4 in ovarian cancers 
is significantly associated with high tumor grade and advanced disease stage (173). 
Aberrant expression of DLX4 in breast cancers correlates with invasiveness (176). 
Upregulation of DLX4 has also been reported in other types of cancers, including 
leukemia, choriocarcinoma, prostate and lung cancers (172, 177-179). The 
upregulation of DLX4 in tumors arising from a wide variety of organ sites raises the 
strong possibility that DLX4 controls a pathogenic mechanism that is common to 
multiple types of tumors. 
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Table 5. Aberrant expression of DLX4 in tumors 
 
Cancer Expression pattern in tumors Functional significance Reference 
Ovarian 
 
Expressed in ovarian carcinomas 
and correlates with high tumor grade 
and disease stage. 
Induces tumor vascularization by inducing 
expression of VEGF and FGF-2.  
(173) 
Breast  Highly expressed in invasive tumors.  Represses expression of BRCA1. Induces 
expression of bcl-2 and inhibits TNF-α-
induced apoptosis in breast cancer cells. 
(176, 187-
190) 
Leukemia Highly expressed in chronic 
lymphocytic leukemia and acute 
lymphoblastic leukemia.  
Expression in leukemic cells increases 
clonogenicity. 
(172) 
Prostate Expressed in 70% of prostatic 
adenocarcinomas. 
 (177) 
Lung Expressed at higher levels in tumors 
than in adjacent normal tissues. 
Enforced expression of DLX4 in metastatic 
lung cancer cells inhibits metastasis.  
(178, 179) 
Chorio-
carcinoma 
Expressed in placenta and 
choriocarcinoma cell lines 
Promotes tumor cell survival (191, 192) 
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 C. CROSS-REGULATION OF TGF SIGNALING AND HOMEOBOX GENES  
 
Increasing evidence indicates that cross-talk between members of the TGF 
super-family and of the DLX homeobox gene family is important for controlling normal 
bone morphogenesis and skeletal patterning (1, 180, 181). On one hand, signaling by 
several TGF super-family members controls transcriptional activity and/or expression 
of DLX transcription factors. For instance, BMP-2 activates DLX3 transcription (182). 
In contrast, Smad6, an antagonist of BMP signaling, inhibits transcriptional activity of 
DLX3 by inhibiting its ability to bind target gene promoters (183).  On the other hand, 
DLX proteins can control TGF signaling by modulating Smad activities. DLX1 has 
been reported to inhibit activin signaling by binding Smad4 (184). Cross-regulation 
between members of the TGF super-family and other homeobox genes has also been 
reported. For example, Mixer and Milk, members of the homeobox Mix family, 
enhance Smad-mediated transcription of Goosecoid in xenopus by interacting and 
recruiting activated Smad complexes to Mixer/Milk binding sites on the Goosecoid 
promoter (181). Group 13 HOX proteins interact with Smad1, Smad2 and Smad5 and 
block their transcriptional activities (185). Conversely, Smad1 has been reported to 
block transcriptional activity of HOXB4, HOXB7, HOXC8 and HOXD10 (186).  
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D. HYPOTHESIS AND SPECIFIC AIMS 
 
The resistance to anti-growth signals is a major hallmark of cancer. TGF-β is a 
key cytokine that inhibits growth of most normal cells by inducing G1 arrest (Figure 6). 
The anti-proliferative effect of TGF-β is orchestrated by a cytostatic program of gene 
responses that are controlled by Smad-dependent mechanisms (Figure 1). Central to 
this cytostatic program are activation of the CDK inhibitors, p15Ink4B and p21WAF1/Cip1, 
and repression of the growth-promoting transcription factors, c-myc and Ids (Figure 6). 
Binding affinity and selectivity of Smad complexes for target gene promoters are 
governed by Smad interactions with other DNA-binding factors. Cooperative 
interactions between Smad proteins and the Sp1 transcription factor are central to 
TGF-β-mediated induction of p15Ink4B and p21WAF1/Cip1 transcription (Figure 4A). Most 
types of cancers are resistant to the anti-proliferative effect of TGF-β. This resistance 
has been attributed to TGF-β receptor and/or Smad mutations in some types of cancer 
(Table 2). However, the rareness of these mutations in many other tumors indicates 
that resistance to the anti-proliferative effect of TGF-β also stems from other molecular 
aberrations (Table 2). 
 
DLX4 is a member of the DLX homeobox gene family. Unlike most other 
homeobox genes that have been studied to date, DLX4 is expressed in a wide range 
of different malignancies. Mounting evidence indicates that cross-talk between the 
members of the TGF super-family and DLX genes is important for controlling normal 
bone morphogenesis and skeletal patterning (Section C). My central hypothesis is that 
DLX4 promotes tumor growth by modulating the TGF-β signaling pathway in tumors. 
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My overall goal is to determine whether and how DLX4 blocks the anti-proliferative 
effect of TGF-β in tumors.  
 
The specific aims of my thesis project are to determine: 
1) whether DLX4 inhibits TGF-β-induced, Smad-dependent responses 
2) whether DLX4 blocks Smad transcription activity 
3) whether DLX4 represses Smad/Sp1-mediated transcription 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
1. Plasmids 
 
A BP1 cDNA that contains the full-length coding region of human DLX4 (172) 
was provided by Dr. Patricia Berg (George Washington University). FLAG-tagged 
DLX4 was cloned into the pIRES-EGFP2 and pRetroQ vectors (Clontech, Palo Alto, 
CA). DNA fragments encoding different DLX4 domains were subcloned into pET41 
GST vectors (Novagen, Gibbstown, NJ) as described in Figure 29A. DLX4 shRNAs 
and non-targeting shRNAs were purchased from OriGene Technology (Rockville, MD). 
GST-tagged Smad2 and Smad4 plasmids were provided by Dr. Fang Liu (Rutgers 
University). Smad2, Smad3 and Smad4 cDNAs were purchased from OriGene 
Technology. MH2 and linker domains of Smad2 and Smad3, described in Figure 23, 
were subcloned into the pFA-CMV plasmid containing the GAL4-DBD (Stratagene, La 
Jolla, CA). The GAL4-driven pRF-Luc reporter construct was also purchased from 
Stratagene. The pGL2 F-Luc reporter vector was purchased from Promega. The c-myc 
promoter reporter construct, pBV-MYC(Del4) and pSBE4-Luc reporter construct 
containing four tandem SBE elements (193, 194) were provided by Dr. Bert Vogelstein 
(Johns Hopkins University). The Cignal Sp1 reporter construct containing a synthetic 
promoter comprising tandem Sp1-binding sites was purchased from SABiosciences 
(Frederick, MD). Sp1 cDNA was provided by Dr. Keping Xie (MD Anderson Cancer 
Center). pGL3 reporter constructs (p15-WT and p15-SBE-mt) containing wild-type and 
mutant p15Ink4B promoter sequences (51) were provided by Drs. Xiao-Fan Wang (Duke 
University Medical Center) and Xin-Hua Feng (Baylor College of Medicine). The Id1 
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promoter construct was provided by Dr. Robert Benezra (Memorial Sloan-Kettering 
Cancer Center) (195). The BRE-Luc reporter construct (196) was provided by Dr. 
Peter ten Dijke (Netherlands Cancer Institute).  
 
2. Antibodies and other reagents 
 
Antibodies (Abs) were purchased from commercial sources as follows: DLX4 
Abs for immunoblotting Abcam (Cambridge, MA) and Abnova Corporation (Taipei, 
Taiwan), for immunoprecipitation (Santa Cruz Biotechnology, Santa cruz, CA).  
Smad2, phospho-Smad2 (Ser465/467), Smad3, Smad4, p15Ink4B, c-myc (Cell 
Signaling Technology, Danvers, MA); p21WAF1/Cip1 (Calbiochem, Gibbstown, NJ); Sp1, 
E-cadherin (Zymed Laboratories, Carlsbad, CA); N-cadherin (BD Biosciences, San 
Jose, CA); actin, FLAG-M2 (Sigma-Aldrich, St. Louis, MO); lamin A/C and Smad2/3 
(Santa Cruz Biotechnology), HRP-conjugated secondary Abs (Bio-Rad, Hercules, CA), 
Alexa Fluor 594-conjugated secondary Abs (Invitrogen, Carlsbad, CA). Recombinant 
Sp1 protein, TGF-β and BMP-4 were purchased from Promega (Madison, WI), Sigma-
Aldrich and R&D Systems (Minneapolis, MN), respectively.  
 
3. Cell lines  
 
HepG2 cells were provided by Dr. Michelle Barton (MD Anderson Cancer 
Center). Mv1Lu cells were purchased from American Type Culture Collection 
(Manassas, VA). Both cell lines were cultured in MEM medium supplemented with 
10% FBS, 2mM glutamine and penicillin-streptomycin. NMuMG and MDA-MB-468 
cells were purchased from American Type Culture Collection (Manassas, VA) and 
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cultured in GIBCO® RPMI-1640 Medium supplemented with 10% FBS, 2mM 
glutamine and penicillin-streptomycin. Ampho-293 cells (provided by Dr. Douglas 
Boyd, MD Anderson Cancer Center) and MCF-7 cells (provided by Dr. Francois-Xavier 
Claret, MD Anderson Cancer Center) were cultured in DMEM medium supplemented 
with 10% FBS, 2mM glutamine and penicillin-streptomycin. 
 
4. Protein over-expression and knock-down  
 
For generating stable lines, FLAG-tagged DLX4 cDNA was subcloned into the 
pRetroQ vector (Clontech) and the retroviral construct was used to transfect Ampho-
293 cells. Supernatants were harvested 2 days thereafter and used to infect target 
cells. Stable lines were selected by puromycin (0.5 µg/ml). For studying Smad-
dependent growth inhibition, Smad4 was transiently expressed in MDA-MB-468 cells 
that lack Smad4. For transient expression, cells were transfected with recombinant 
plasmids using FuGENE6 reagent following manufacturer's instructions (Roche 
Applied Biosciences, Indianapolis, IN). To assay the effect of DLX4 knock-down, MCF-
7 cells were transfected with shRNA constructs (empty vector, non-targeting and two 
DLX4 shRNAs) purchased from OriGene Technology using FuGENE6 reagent. 
 
5. Cell growth assays  
 
Cells were seeded in 96-well plates at 4,000 cells per well in 100 µl medium  
and cultured for 2 days in complete medium containing 0, 1, 3, 10, 30 and 100 ng/ml 
TGF-β. MTT assays were performed following manufacturer's instructions (Roche 
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Applied Biosciences). Briefly, 10 µl of MTT labeling reagent was added to each well 
(final MTT concentration 0.5 mg/ml). The plate was incubated for 4 hours in a 
humidified atmosphere (37°C, 5% CO2) then 100 μl of solubilization solution was 
added to each well. The plate was incubated overnight in a humidified atmosphere.  
The spectrophotometrical absorbance (570 nm) was measured.  Experiments were 
done in triplicate and repeated two times. 
 
6. Cell cycle analysis 
 
Cells were seeded in 10 cm dishes to reach 30% confluence the following day. 
Cells were serum-starved overnight and then cultured in complete medium with and 
without addition of TGF-β (10 ng/ml) for 18 h. Cells were harvested and washed in 
phosphate-buffered saline (PBS). Cells were then fixed in 1 ml of 4% 
paraformaldehyde in PBS (pH 7.4) for 20 minutes on ice. Cells were washed in PBS, 
resuspended in 1 ml of cold 70% ethanol and kept at -200C. Following centrifugation at 
800 x g, cells were washed with PBS then stained with 1 ml of staining solution 
containing 40 μg/ml propidium iodide (Sigma-Aldrich) and RNaseA at 370C for 30 
minutes in the dark. Distribution throughout the cell cycle was determined by flow 
cytometric analysis. 
 
7. Reporter Assays   
 
Cells were seeded at 4–5 x 104 cells/well in 12-well plates and co-transfected 
with expression plasmids (400 ng), reporter plasmid (100 ng) and pRL-CMV Renilla 
luciferase (R-Luc) reporter plasmid (0.5 ng) (Promega) for normalizing transfection 
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efficiency using FuGENE6 reagent (Roche Applied Biosciences). At 24 hours after 
transfection, cells were cultured for an additional 18 hours with and without TGF-β or 
BMP-4. Luciferase activities were assayed using the Dual-reporter assay kit 
(Promega) and measured on a Monolight 2010 luminometer (Analytical Luminescence 
Laboratory, Ann Arbor, MI). Experiments were performed in triplicate and repeated two 
times. GAL4 reporter assay were performed as above with some modifications. Briefly, 
DLX4 or empty vector was co-transfected with GAL4-driven reporter construct and 
GAL4-DBD/Smad2 and GAL4-DBD/Smad3. TGF-β treatment and luciferase assays 
were performed as described above. 
 
8. Immunofluorescence staining 
 
Cells (5x104/well) were seeded in 2-well chamber slides. Cells were serum 
starved overnight and then treated with TGF-β for 1 hour. Cells were washed with PBS 
and fixed with 1% paraformaldehyde (in PBS, pH 7.4) for 20 minutes on ice. Fixed 
cells were washed with PBS two times and permeablized with 0.1% Triton X-100 (in 
PBS) for 20 minutes on ice. Cells were then washed with PBS and blocked with 1% 
goat serum in PBS for 30 minutes at 40C and stained with Abs to Smad2, DLX4, E-
cadherin, or FLAG Ab (1:200). Cells were washed 5 times in PBS containing 1% BSA. 
Staining was detected by Alexa Fluor 594-conjugated secondary Ab (1:1000). Cells 
were also stained with 4',6-diamidino-2-phenylindole (DAPI) (1:1000) to visualize 
nuclei. 
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9. Immunoblotting 
 
To determine protein expression levels, cells were lysed in M-PER buffer 
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions. 
Total cell lysates were electrophoresed on 6 - 15% SDS gels, then transferred to 
polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Piscataway, 
NJ) and blocked with 5% nonfat milk in PBS with 0.1% Tween-20 (PBS-T). 
Immunoblotting was performed with primary Abs at recommended dilution provided by 
manufacturers in PBS-T containing 5% nonfat milk except for phospho Smad2 Ab 
which was prepared in PBS-T with 5% BSA. Membranes were hybridized with primary 
Abs overnight at 4oC then washed with PBS-T buffer. Secondary Abs were diluted at 
1:2000 in PBS-T with 5% nonfat milk and incubated with membranes for 1-2 hours at 
room temperature. Membranes were then washed with PBS-T buffer and incubated 
with ECL Western blotting detection reagent (Amersham Biosciences) and exposed to 
autoradiographic film.   
 
10. Immunoprecipitation 
 
Cell lysate preparation:  
Cells were plated to reach 70-80% confluence and were transfected with DLX4 
or empty vector. At 24 hours after transfection, cells were serum-starved overnight and 
then treated without or with 10 ng/ml TGF-β for 1 hour. To prepare whole cell lysates, 
cells were washed with PBS buffer and lysed in native buffer (20 mM Tris-HCl pH 8.0, 
100 mM NaCl, 1% NP-40, 10% glycerol, 2 mM EDTA) supplemented with protease 
and phosphatase inhibitors for 10 minutes on ice. Cells were then sonicated. To 
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reduce viscosity caused by genomic DNA, benzonase enzyme was added. Lysates 
were centrifuged at 12000 x g for 10 minutes and supernatants were collected. Whole 
cell lysates were used immediately for immunoprecipitation or stored at -80oC. To 
prepare nuclear extracts, cells were lysed in cytosol lysis buffer (10 mM HEPES pH 
7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT plus protease and phosphatase inhibitors), 
followed by centrifugation at 800 x g for 10 minutes. Nuclear pellets were washed then 
lysed in native buffer (Tris pH 8.0 20mM, 100mM NaCl, NP40 1%, Glycerol 10% EDTA 
2mM) plus protease and phosphatase inhibitors. The lysates were sonicated then 
centrifuged at 12000 x g for 10 minutes. Supernatants were transferred to a fresh 
eppendorf tube. Nuclear lysates were used immediately for immunoprecipitation or 
stored at -80oC 
 
Immunoprecipitation:  
Whole cell extracts (1 mg) or nuclear extracts (500 ug) were pre-cleared with 
protein G agarose (Amersham Biosciences) by rotating at 4°C for 30 minutes. Lysates 
were then incubated with anti-FLAG-M2 affinity gel (Sigma-Aldrich) for 4-12 hours at 
4°C. Where unconjugated primary Abs were used, lysates were incubated with the 
Abs for 12 hours at 4°C then further incubated with protein G agarose for 1 hour at 
4°C. Immunoprecipitates were washed five times with native buffer and subjected to 
SDS PAGE and immunoblot analysis.   
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11. Oligonucleotide pull-down assays 
 
Preparation of biotinylated oligonucleotides:  
Sense and antisense oligomers were designed to cover the p15Ink4B promotor 
region from positions -108 to -39 (Figure 31A and Table 6). The sense oligomer was 
labeled with biotin at the 5’ end. Oligos were generated by Sigma-Aldrich. Oligomers 
were dissolved in H2O. Oligomers were annealed by incubating at 98oC for 10 minutes 
followed by slow cooling down to room temperature overnight. The annealed product 
was verified by agarose DNA electrophoresis. 
 
DNA pull-down:  
Nuclear lysates were prepared as described for immunoprecipitation except that 
lysates were dissolved in binding buffer (10 mM HEPES pH 7.9; 100 mM KCl, 5 mM 
MgCl2, 1 mM EDTA, 10% glycerol, 1 mM DTT, 0.5% NP-40) plus proteinase inhibitor 
cocktail. Nuclear lysates were pre-cleared with strepavidin agarose for 30 minutes at 
4°C. Biotin-labeled oligonucleotides were added to the lysate and incubated overnight 
at 4°C with rotating. The lysate was then added to pre-washed streptavidin-conjugated 
agarose beads and further rotated at 4°C for 1 hour. Beads were washed 4 times with 
binding buffer. DNA bound proteins were eluted from strepavidin-conjugated agarose 
beads with 1X SDS sample (Laemmli) buffer at 85°C for 5 minutes. The samples were 
then subjected to SDS-PAGE and immunoblotting. 
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Table 6. p15Ink4B oligomers for oligonucleotide pull-down assays 
 
Name  Sequence  
Sense strand  5'-BIOTIN-
GCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGG
GGGTGGGGAGACGCCGGCCCCTTG-3’  
Antisense strand  5'-
AAGGGGCCGGCGTCTCCCCACCCCCTTAGGCTCCGCCCCCTGTCCG 
CTGTGATCGCCGGGAGGCCAGGC-3'  
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12. In vitro binding assays 
 
Preparation of GST fusion and 35S-labeled proteins:  
GST fusion proteins containing full-length DLX4, truncated DLX4, Smad2 and 
Smad4 were produced in E.coli and purified by glutathione beads (Amersham 
Biosciences) following the manufacturer’s instructions. 35S-labeled DLX4, Smad4 and 
Sp1 were synthesized in vitro from the T7 promoter using the TNT coupled translation 
kit (Promega) following the manufacturer’s instructions. 
 
Binding assays:  
GST fusion protein (1 µg) bound to glutathione-sepharose beads was pre-
incubated with 0.5 mg/ml BSA in binding buffer (20 mM Tris [pH8.0], 100 mM NaCl, 
0.1% NP40, 2 mM EDTA, plus proteinase inhibitor cocktail) for 1 hour. 35S-labeled 
proteins were pre-cleared by incubating with glutathione-sepharose beads in binding 
buffer for 1 hour. GST fusion protein was then incubated with pre-cleared 35S-labeled 
protein for 2 hours. Beads were then extensively washed with binding buffer for 5 
times. Associated proteins were subjected to SDS-PAGE and visualized by 
autoradiography. 
 
13. Total RNA extraction and qPCR 
 
Total RNA extraction:  
Total RNA was extracted using TRIzol reagent (Invitrogen) following 
manufacturer’s instructions. Extracted RNA was treated with DNAseI and purified 
using the RNeasy kit (Qiagen, Valencia, CA).  
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qPCR:  
Purified total RNA (500 ng) was used to synthesize cDNA by random priming 
using the RT² First Strand Kit (SABiosciences). cDNA and primers were included in a 
reaction (20 ul) with the RT² SYBR® Green qPCR Master Mix (SABiosciences). 
Reactions were run on the AB7500 system (Applied Biosystems, Carlsbad, CA) with 
40 cycles of 950C for 15 seconds and 600C for 1 minute according to the standard 
manufacturer’s program. Primers were predesigned to amplify a 98 bp region located 
at positions 1278-1297 of the 3’ untranslated region of DLX4 gene (SABioscience). 
Primer specificity was confirmed by including a dissociation curve at the end of thermal 
cycles. Data analysis was performed using the delta-delta Ct method. Levels of DLX4 
expression were normalized to β-actin. 
 
14. Gel-shift assays  
 
32P-labeled probe preparation:  
Oligomers were designed to contain sense and antisense sequences -88 to -64 
of the p15Ink4B promoter with 5' overhangs for labeling (Figure 35A and Table 7). 
Double-stranded oligos were generated by incubating sense and antisense oligomers 
at 980C for 10 minutes followed by slow cooling to room temperature overnight. 32P-
labeled probe was produced by end-filling using the Klenow enzyme (Roche Applied 
Biosciences) following manufacturer’s instructions. The 32P-labeled probe was then 
purified through NICK™ Column (Amersham Biosciences) and eluted in TE buffer to a 
final concentration of 1 ng/ul. 
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Table 7. p15Ink4B oligomers for gel-shift assays 
 
Name  Sequence  
Sense strand  5'-CAGCGGACAGGGGGCGGAGCCTAAG-3’  
Antisense strand  5'-CTTAGGCTCCGCCCCCTGT-3'  
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Gel-shift reaction:  
EMSA was performed in 25 µl reactions. Recombinant Sp1 protein (100 ng) 
was incubated with increasing amounts of in vitro translated FLAG-DLX4 and FLAG-
tag synthesized from TNT coupled reticulocyte lysates (Promega) for 20 minutes in 
binding buffer (10 mM Tris-HCl [pH 7.5], 1 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA, 
4% glycerol, 0.5 mM DTT, 1 µg poly(dI-dC).poly(dI-dC)) at 230C. 1ng of 32P-labeled 
probe was added to the binding reaction and incubated for an additional 20 minutes. 
The reactions were electrophoresed on a 5% nondenaturing polyacrylamide gel. The 
gel was dried and exposed to autographic film. 
 
15. Chromatin immunoprecipitation  
 
Chromatin immunoprecipitation (ChIP) was performed using the ChIP Assay Kit 
(Upstate; Temecula, CA) following manufacturer’s instructions with modifications. 
Briefly, cells were cross-linked by adding formaldehyde to 1% final concentration at 
room temperature for 10 minutes. Formaldehyde was then quenched by adding 
glycine and incubated at room temperature for 5 minutes. The cells were then washed 
with PBS and scraped off dishes. Cell suspensions were centrifuged and the 
supernatant was discarded. Cells were lysed in SDS lysis buffer containing protease 
inhibitors and sonicated to generate DNA fragments of ~200-1000 base pairs in length. 
Sheared chromatin was then pre-cleared with Protein G agarose then incubated with 4 
ug of Abs to Sp1 (Zymed Laboratories), Smad4 (Cell signal), Smad2/3, and normal 
IgG (Santa Cruz Biotechnology) overnight. Protein G agarose was then added and 
incubated for 1 hour. The protein G agarose-antibody/chromatin complex was 
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extensively washed, followed by elution of immunoprecipitated complexes and 
reversal of cross-links. Protein and RNA were removed by incubating with RNase A 
and proteinase K. Eluted DNA fragments were purified and used for PCR reactions to 
amplify a 535 bp fragment of the p15Ink4B promoter (Table 8). The amplified fragment 
was confirmed by DNA sequencing.  
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Table 8. p15Ink4B primer sequences for ChIP PCR 
 
Name  Sequence  
Sense strand  5'-TATGGTTGACTAATTCAAACAG-3’  
Antisense strand  5'-GCAAAGAATTCCGTTTTCAGCT-3'  
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CHAPTER 3: DLX4 INHIBITS TGF-β-INDUCED, SMAD-DEPENDENT RESPONSES 
 
 
A. RATIONALE 
 
TGF-β inhibits growth of most types of normal cells by inducing cell cycle arrest. 
The anti-proliferative effect of TGF-β is orchestrated by a cytostatic program of gene 
responses that principally involves activation of the CDK inhibitors p15Ink4B and 
p21WAF1/Cip1 (38, 51) and repression of the growth-promoting transcription factors c-myc 
and Ids (52, 59) (Figure 6). In many types of tumors, the anti-proliferative effect of 
TGF-β is abolished (3, 4). Resistance to the anti-proliferative effect of TGF-β has been 
attributed to TGF-β receptor and/or Smad mutations in some types of tumors, 
particularly those of gastrointestinal origin (112, 114, 115) (Table 2). However, the 
rareness of these mutations in many other types of tumors indicates that resistance to 
the anti-proliferative effect of TGF-β also stems from other aberrations (112) (Table 2). 
  
Cross-talk between members of the DLX gene family and the TGF super-family 
is important for controlling bone morphogenesis and skeletal patterning (1, 180, 181). 
The homeobox gene DLX4 is not expressed in most normal adult tissues, but is 
expressed in a wide range of tumors (Table 5). This raises the possibility that DLX4 
promotes tumorigenesis via a mechanism common to multiple types of tumors. The 
goal of my studies in this chapter is to determine whether DLX4 blocks TGF-β-induced, 
Smad-dependent responses that are central to the anti-proliferative effect of TGF-β.  
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B. RESULTS 
 
1. DLX4 blocks TGF-β-mediated growth inhibition 
 
To determine whether DLX4 blocks the anti-proliferative effect of TGF-β, we first 
assayed the effect of DLX4 on cell growth in the non-tumorigenic lung epithelial cell 
line Mv1Lu. Mv1Lu is a well-established model for studying TGF-β-induced growth 
arrest (197, 198). Growth of Mv1Lu cells was inhibited by TGF-β in a dose-dependent 
manner (Figure 14A). In contrast, enforced expression of DLX4 in Mv1Lu cells 
decreased the sensitivity to TGF-β (Figure 14A). This observation indicates that DLX4 
blocks the growth-inhibitory effect of TGF-β. To confirm this finding, the effect of 
knocking-down DLX4 on cell growth was assayed. DLX4 was knocked-down by using 
shRNAs that targeted different sites of DLX4 (sh90 and sh92). Knockdown of DLX4 in 
MCF-7 breast cancer cells increased sensitivity to TGF-β in cell viability assays (Figure 
14B). The ability of these shRNAs to knock-down DLX4 in MCF-7 cells was confirmed 
by Western blot (Figure 15A) and also by qPCR and immunofluorescence staining 
(Figure 15B, 15C). 
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Figure 14. DLX4 blocks TGF-β-mediated growth inhibition 
[A] Vector-control (-DLX4) and +DLX4 stable Mv1Lu lines were cultured with the 
indicated concentrations of TGF-β for 2 days. Changes in cell growth were determined 
by MTT assay, and expressed relative to growth of cells incubated without TGF-β. 
Shown are results of two independent experiments each performed in triplicate. [B] 
Transfected MCF-7 cells were cultured with the indicated concentrations of TGF-β for 
2 days. Changes in cell growth were determined by MTT assay.  
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Figure 15. Knockdown of DLX4 
MCF-7 cells were transfected with empty vector, non-targeting shRNA and DLX4 
shRNAs (sh90, sh92). [A] At 2 days after transfection, DLX4 levels were assayed by 
Western blot. [B] DLX4 transcript levels in transfected MCF-7 cells were assayed by 
qPCR using SYBR®Green qPCR Master Mix and DLX4 primers purchased from 
SABiosciences. [C] At 2 days after transfection, endogenous DLX4 in cells was 
detected by staining using DLX4 Ab (red). Nuclei were visualized by staining with 
DAPI (blue). Bar, 20 µm. 
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2. DLX4 blocks the ability of TGF-β to induce G1 arrest 
 
TGF-β induces cell cycle arrest in G1 phase (198, 199). We determined whether 
DLX4 blocks the ability of TGF-β to induce G1 arrest by performing cell cycle analysis. 
Treatment of vector-control Mv1Lu cells with TGF-β led to significant accumulation of 
cells in G1 phase (Figure 16A). However, enforced expression of DLX4 in Mv1Lu cells 
inhibited the induction of G1 arrest by TGF-β (Figure 16A). Similarly, enforced 
expression of DLX4 in the non-tumorigenic mammary epithelial cell line NMuMG also 
inhibited TGF-β-induced G1 arrest (Figure 16B). Conversely, knockdown of DLX4 in 
MCF-7 cells was observed to increase the proportion of cells in G1 phase (Figure 
16C). These data indicate that DLX4 inhibits TGF-β-mediated G1 arrest. 
 
3. DLX4 blocks Smad-dependent growth inhibition 
 
TGF-β inhibits cell growth principally via Smad-dependent mechanisms that require 
Smad4 (3). Because TGF-β can also inhibit cell growth via Smad-independent 
mechanisms (60), we determined whether DLX4 blocks Smad-dependent growth 
inhibition. The effect of DLX4 on cell growth was assayed using the MDA-MB-468 
breast cancer cell line that has the homozygous deletion of Smad4 (122). Growth of 
MDA-MB-468 cells was not inhibited by TGF-β (Figure 17). In contrast, reconstitution 
of Smad4 in these cells increased responsiveness to TGF-β (Figure 17). This Smad4- 
dependent responsiveness to TGF-β was abrogated when DLX4 was expressed 
(Figure 17). These results confirm our finding that DLX4 opposes the anti-proliferative  
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Figure 16. DLX4 blocks TGF-β-induced G1 arrest 
[A] Mv1Lu lines were treated without and with 10 ng/ml TGF-β for 18 hours. [B] 
Transfected MCF-7 cells were treated without and with TGF-β (10 ng/ml) for 18 hours. 
[C] Vector-control (-DLX4) and +DLX4 NMuMG cells were treated without and with 
TGF-β (5 ng/ml) for 18 hours. Indicated are the proportions of cells in G1, S and G2/M 
phases determined by flow cytometric analysis of propidium iodide-staining. 
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Figure 17. DLX4 blocks Smad-dependent growth inhibition 
Vector-control (-DLX4) and +DLX4 stable MDA-MB-468 lines were transfected with 
Smad4. At 24 hours thereafter, cells were cultured without and with TGF-β (10 ng/ml) 
for 2 days and changes in cell growth were examined by MTT assay. 
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effect of TGF-β, and indicate that DLX4 blocks TGF-β-mediated growth inhibition in a 
Smad-dependent manner. 
 
4. DLX4 inhibits gene responses of the TGF-β cytostatic program  
 
TGF-β inhibits cell growth by controlling a cytostatic program of gene responses 
that includes activation of p15Ink4B and p21WAF1/Cip1 transcription and repression of c-
myc and Id transcription (38, 51, 52, 59). In subsequent experiments, we determined 
whether DLX4 inhibits gene responses of this cytostatic program. 
 
4.1. DLX4 inhibits TGF-β-mediated induction of CDK inhibitors 
 
Treatment of vector-control Mv1Lu cells with TGF-β induced expression of p15Ink4B 
(Figure 18A). However, enforced expression of DLX4 in Mv1Lu cells blocked TGF-β-
induced p15Ink4B expression (Figure 18A). To determine whether this blocking effect 
was Smad-dependent, we assayed the expression of TGF-β response genes in MDA-
MB-468 cells. Treatment of MDA-MB-468 cells with TGF-β did not induce expression 
of p21WAF1/Cip1 (Figure 18B). When MDA-MB-468 cells were reconstituted with Smad4, 
p21WAF1/Cip1 expression was induced by TGF-β. However, enforced expression of DLX4 
blocked this induction (Figure 18B). These results indicate that DLX4 inhibits TGF-β-
mediated, Smad-dependent induction of CDK inhibitor expression. 
 
 61 
 
 
Figure 18. DLX4 blocks Smad-dependent cytostatic gene responses 
[A] Western blot analysis of Mv1Lu lines following treatment without and with TGF-β 
(10 ng/ml) for 16 hours. [B] Western blot analysis of MDA-MB-468 lines following 
treatment without and with TGF-β for 16 hours.  
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4.2. DLX4 blocks Smad-dependent transcription of p15Ink4B  
 
TGF-β induces transcription of p15Ink4B and p21WAF1/Cip1 by similar Smad-
dependent mechanisms (38, 51). Because DLX4 is a transcription factor, it is likely 
that DLX4 blocks Smad-mediated transcription of these genes. To investigate this 
possibility, we focused on the well-characterized p15Ink4B promoter. The first 113 bp of 
the p15Ink4B promoter are essential for induction by TGF-β and contain two Smad-
binding elements (SBEs) (51). We initially determined whether DLX4 inhibits the ability 
of TGF-β to induce p15Ink4B promoter activity by reporter assays using a construct 
driven by the minimal p15Ink4B promoter (-113 to +70) (p15-WT). Activity of this minimal 
promoter was induced by TGF-β in vector-control Mv1Lu cells, and this induction was 
abolished by mutation of the SBEs (Figure 19A). Enforced expression of DLX4 in 
Mv1Lu cells abolished the induction of wild-type p15Ink4B promoter activity by TGF-β 
(Figure 19A). DLX4 also modestly inhibited activity of the SBE-mutant promoter  
(Figure 19A). This result suggests that DLX4 also can block basal p15Ink4B promoter 
activity independently of TGF-β/Smad signaling. To confirm that DLX4 blocks Smad-
mediated induction of p15Ink4B, we assayed p15Ink4B promoter activity in Smad4-
deficient MDA-MB-468 cells. Wild-type p15Ink4B promoter activity was unresponsive to 
TGF-β in MDA-MB-468 cells. TGF-β responsiveness was conferred when Smad4 was 
expressed in these cells. However, this Smad4-dependent responsiveness was 
eliminated when DLX4 was co-expressed (Figure 19B). Together, these findings 
demonstrate that DLX4 blocks Smad-mediated transcription of p15Ink4B. 
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Figure 19. DLX4 inhibits TGF-β-mediated induction of p15Ink4B promoter activity 
[A] Mv1Lu cells were co-transfected with empty vector (grey bar) or DLX4 (black bar), 
together with reporter plasmids containing no promoter (pGL2 vector), p15Ink4B 
promoter sequences (-113 to +70) (p15-WT), and p15Ink4B promoter with mutated 
SBEs (p15-SBE-mt). Cells were cultured without and with TGF-β for 18 hours, and 
assayed for F-Luc activity. [B] Reporter assays using the p15-WT reporter plasmid 
were performed using transfected MDA-MB-468 lines. Shown are relative F-Luc 
activities in three independent experiments each performed in duplicate. Values were 
normalized by activity of co-transfected R-Luc.  
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4.3. DLX4 induces c-myc expression independently of TGF-β/Smad signaling 
 
In subsequent experiments, we determined whether DLX4 blocks TGF-β-
mediated repression of c-myc expression. Enforced expression of DLX4 induced c-
myc expression in MDA-MB-468 cells, irrespective of the absence or presence of 
Smad4 (Figure 18B). Because DLX4 induced the level of c-myc protein independently 
of TGF-β/Smad signaling, we investigated the effect of DLX4 on c-myc induction by 
assaying c-myc promoter activity. Activity of the c-myc promoter was repressed by 
TGF-β in vector-control Mv1Lu cells (Figure 20A). However, enforced expression of 
DLX4 in Mv1Lu cells induced c-myc promoter activity both in the absence and 
presence of TGF-β stimulation (Figure 20A). In converse experiments, knock-down of 
DLX4 inhibited c-myc promoter activity in MCF-7 cells in the absence of TGF-β 
stimulation (Figure 20B). TGF-β treatment of DLX4 knock-down cells further inhibited 
c-myc promoter activity (Figure 20B).  These results suggest that DLX4 blocks the 
ability of TGF-β to repress c-myc expression and can also induce c-myc expression 
independently of TGF-β/Smad signaling.   
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Figure 20. DLX4 induces c-myc promoter activity 
[A] Mv1Lu cells were co-transfected with empty vector (grey bar) or DLX4 (black bar), 
together with empty pBV-Luc vector or with pBV-MYC(Del4) reporter plasmid that 
contains 900 bp of c-myc P1 and P2 promoter sequences. Transfected cells were 
cultured without and with TGF-β (10 ng/ml) for 18 hours, and assayed for F-Luc 
activity. [B] Reporter assays for c-myc promoter activity were likewise conducted using 
MCF-7 cells that were co-transfected with non-targeting shRNA (grey bar) and DLX4 
(sh90) shRNA (black bar). 
 
 
 
 66 
 
 
5. DLX4 inhibits TGF-β-induced EMT  
 
In addition to its anti-proliferative effect, TGF-β is well-known to induce EMT via 
Smad and non-Smad mechanisms (3, 4) (Figure 8). Because our results demonstrate 
that DLX4 blocks TGF-β-mediated growth inhibition in a Smad-dependent manner, it is 
possible that DLX4 also blocks the ability of TGF-β to induce EMT. To address this 
possibility, we used the NMuMG cell line, a well-established model for studying TGF-β-
induced EMT. Smad4 has been demonstrated to be essential for TGF-β-induced EMT 
in several cell types, including NMuMG cells (200). TGF-β treatment of vector-control 
NMuMG cells induced profound epithelial-to-fibroblastic morphologic transformation 
(Figure 21A). E-cadherin expression was lost, whereas N-cadherin was induced in 
vector-control NMuMG cells following TGF-β treatment (Figures 21B, 21C). In contrast, 
enforced expression of DLX4 in NMuMG cells blocked the down-regulation of E-
cadherin and induction of N-cadherin (Figures 21B, 21C). Additionally, epithelial 
morphology was considerably retained in TGF-β-treated +DLX4 NMuMG cells (Figure 
21A). These results indicate that DLX4 can inhibit TGF-β-induced EMT. 
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Figure 21. Effect of DLX4 on TGF-β-induced EMT 
Vector-control (-DLX4) and +DLX4 NMuMG cells were incubated without or with TGF-
β (5 ng/ml) for 24 hours. [A] Morphology of cells was visualized by phase-contrast 
microscopy. Bar, 50 µm. [B] E-cadherin expression was detected by 
immunofluorescence staining (red). Nuclei were visualized by staining with DAPI 
(blue). Bar, 20 µm. [C] Western blot analysis of DLX4, E-cadherin and N-cadherin.  
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C. CONCLUSION 
 
The studies in this chapter demonstrate that DLX4 blocks the anti-proliferative 
effect of TGF-β by inhibiting the TGF-β-mediated cytostatic program of gene 
responses that cause G1 arrest. The studies demonstrate that DLX4 blocks the ability 
of TGF-β to induce p15Ink4B and p21WAF1/Cip1 expression, and that this blocking effect 
occurs via Smad-dependent mechanisms. In addition, the studies demonstrate that 
DLX4 blocks the ability of TGF-β to repress c-myc expression, and can also induce c-
myc expression independently of TGF-β/Smad signaling. Furthermore, our findings 
indicate that DLX4 blocks the ability of TGF-β to induce EMT in cells that normally 
undergo TGF-β-induced EMT in a Smad-dependent manner. Together, our findings 
that DLX4 blocks TGF-β-mediated, Smad-dependent growth inhibition and also EMT 
indicate that DLX4 inhibits a core component of the TGF-β/Smad signaling pathway. 
Identification and characterization of this inhibitory mechanism will be the focus of 
Chapter 4 and Chapter 5. 
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CHAPTER 4: DLX4 BLOCKS SMAD TRANSCRIPTIONAL ACTIVITY 
 
 
A. RATIONALE 
 
Binding of TGF-β to TβRII leads to recruitment and activation of TβRI which in 
turn phosphorylates R-Smads. Phosphorylated R-Smads translocate to the nucleus, 
where they form heteromeric complexes with Smad4 and other DNA-binding factors to 
regulate gene transcription (9, 12) (Figure 2). TGF-β/Smad signaling is modulated at 
multiple levels. These include binding of TGF-β to TβRII, formation of the TβRI-TβRII 
complex, phosphorylation and nuclear localization of R-Smads, and transcriptional 
activity of Smad proteins (Figure 2).  
 
Studies in Chapter 3 demonstrated that DLX4 blocks TGF-β-mediated gene 
responses through Smad-dependent mechanisms. Because DLX4 is a transcription 
factor, we hypothesize that DLX4 blocks TGF-β signaling by interfering with Smad 
transcriptional activity. The goal of the studies in this chapter is to determine whether 
and how DLX4 blocks Smad activity.  
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B. RESULTS 
 
1. DLX4 does not affect phosphorylation, expression and localization of R-
Smads  
 
As discussed in Chapter 1, Smad-dependent transcription is controlled at 
multiple levels, including phosphorylation, expression and nuclear localization of Smad 
proteins (201). Enforced expression of DLX4 in Mv1Lu cells did not alter the 
expression level of Smad2 (Figure 22A). The expression levels of Smad3 and Smad4 
were also not affected by DLX4 (see Figure 27B, discussed later). Furthermore, DLX4 
did not affect TGF-β-induced phosphorylation of Smad2 (Figure 22A). This result also 
implies that DLX4 has no effect on activation of TGF-β receptors. Treatment of vector-
control cells with TGF-β induced rapid translocation of Smad2 from the cytoplasm to 
the nucleus (Figure 22B). Enforced expression of DLX4 did not interfere with this 
translocation of Smad2 (Figure 22B). We also investigated whether TGF-β stimulation 
affected the localization of DLX4. Immunofluorescence staining studies demonstrated 
that DLX4 is predominantly localized in the nucleus and that its nuclear localization is 
not affected by TGF-β stimulation (Figures 22C, 22D). These findings indicate that 
DLX4 most likely inhibits nuclear events downstream of the TGF-β signaling pathway.  
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Figure 22. Phosphorylation, expression levels and localization of Smad and 
DLX4 proteins 
Vector-control (-DLX4) and +DLX4 Mv1Lu lines were serum-starved overnight and 
then treated without and with TGF-β (10 ng/ml) for 30 minutes. [A] Total and 
phosphorylated Smad2 were detected by Western blot. [B] Intracellular localization of 
Smad2 was detected by immunofluorescence staining. Bar, 20 µm. [C] MvL1Lu cells 
that stably express FLAG-DLX4 were serum-starved overnight, and then incubated in 
complete medium for 30 minutes without or with TGF-β (10 ng/ml). Following fixation 
and permeabilization, cells were stained with FLAG Ab (red). [D] Parental MCF-7 cells 
were treated as in [C]. Endogenous DLX4 in cells was detected by staining using 
DLX4 Ab (red). Nuclei were visualized by staining with DAPI (blue). Bar, 20 µm.  
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2. DLX4 blocks transcriptional activity of activated R-Smads 
 
Smad proteins contain two functional domains with an intervening linker region. 
MH1 domains are responsible for binding to SBEs, whereas MH2 domains mediate 
interactions of Smads with one another and with other transcription factors (8, 12) 
(Figure 3). MH2 domains of Smad2 and Smad3 have intrinsic transcriptional activation 
capacity (8). We, therefore, sought to determine whether DLX4 inhibits transcriptional 
activity of Smad2 and Smad3 (Figure 23). 
 
2.1. DLX4 represses transcriptional activity of Smad2  
 
A chimeric expression construct was generated by fusing the GAL4 DNA-
binding domain (DBD) to the linker region and MH2 transcriptional activation domain of 
Smad2 [amino acids 173 to 467]. To determine whether DLX4 represses 
transcriptional activity of Smad2, the GAL4-DBD/Smad2 chimera was co-expressed in 
Mv1Lu cells along with a firefly luciferase (F-Luc) reporter controlled by a synthetic 
promoter comprising five tandem GAL4 binding sites. As shown in Figure 24A, 
transcriptional activity of GAL4-Smad2 was induced by TGF-β in the absence of DLX4. 
However, this activation was abolished when DLX4 was expressed (Figure 24A). 
Similar results were obtained using the hepatoma cell line HepG2, which is responsive 
to TGF-β (Figure 24A). In converse experiments, we observed that knockdown of 
DLX4 in MCF-7 cells increased TGF-β-mediated induction of GAL4-Smad2 activity 
(Figures 24B). 
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Figure 23. Schematic design of GAL4-Smad2/3 chimeras and reporter assay 
Chimeras were constructed in which the linker and MH2 domains of Smad2 and 
Smad3 were fused to the GAL4-DBD. These chimeras were tested for their ability to 
induce a synthetic promoter containing GAL4 binding element (GAL4BE).  
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Figure 24. DLX4 blocks Smad2 transcriptional activity 
[A] Mv1Lu and HepG2 cells were co-transfected with empty vector (grey bar) or DLX4 
(black bar), together with GAL4-driven F-Luc reporter plasmid and with GAL4-Smad2. 
Transfected cells were cultured without and with TGF-β for 18 hours, and assayed for 
F-Luc activity. [B] GAL4-Smad2 activity were likewise assayed in MCF-7 cells that 
were co-transfected with non-targeting shRNA (grey bar) or DLX4 (sh90) shRNA 
(black bar).  
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2.2. DLX4 represses transcriptional activity of Smad3  
 
We also investigated the effect of DLX4 on transcriptional activity of Smad3 by 
generating a chimeric construct in which the GAL4-DBD was fused to the linker region 
and MH2 transcriptional activation domain of Smad3 [amino acids 133 to 425]. As 
observed with our assays using the GAL4-Smad2 chimera, we found that DLX4 
similarly abolished TGF-β-induced transcriptional activity of the GAL4-Smad3 chimera 
in both Mv1Lu and HepG2 cells (Figure 25A). Conversely, knockdown of DLX4 in 
MCF-7 cells enhanced TGF-β-mediated induction of GAL4-Smad3 activity (Figure 
25B).  
 
2.3. DLX4 blocks gene transcription mediated by BMP-activated R-Smads 
 
Smad2 and Smad3 serve as substrates for the TβRI kinase and are activated 
by TGF-β, whereas other R-Smads (Smads 1, 5 and 8) are utilized by the BMP and 
anti-Müllerian receptors (10, 201). We initially tested the ability of DLX4 to inhibit 
transcription induced by other members of the TGF super-family by using a synthetic 
promoter comprising four tandem SBEs (pSBE4-Luc). Activity of this promoter was 
induced by TGF-β treatment of vector-control HepG2 cells (Figure 26A). This induction 
was blocked by DLX4. Similarly, BMP-4 treatment of HepG2 cells induced activity of 
the SBE-driven promoter, whereas DLX4 blocked BMP-4-mediated induction of the 
promoter (Figure 26A). TGF-β- and BMP-specific R-Smads have been reported to 
preferentially bind distinct DNA sequences (196, 202). Indeed, we found that BMP-4 
was not as effective as TGF-β in inducing pSBE4-Luc activity (Figure 26A). We,  
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Figure 25. DLX4 blocks Smad3 transcriptional activity 
[A] Mv1Lu and HepG2 cells were co-transfected with empty vector (grey bar) or DLX4 
(black bar), together with GAL4-driven F-Luc reporter plasmid and with GAL4-Smad3. 
Transfected cells were cultured without and with TGF-β for 18 hours, and assayed for 
F-Luc activity. [B] GAL4-Smad3 activities were, likewise, assayed in MCF-7 cells that 
were co-transfected with non-targeting shRNA (grey bar) or DLX4 (sh90) shRNA 
(black bar).  
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therefore, tested the effect of DLX4 on BMP-induced transcription by using a reporter 
plasmid that contains the BMP-responsive promoter of the Id1 gene. BMP-4 induced 
Id1 promoter activity in vector-control HepG2 cells, whereas expression of DLX4 
blocked BMP-induced Id1 promoter activity (Figure 26B). To confirm this blocking 
effect of DLX4, we used a synthetic promoter comprising two tandem copies of the 
BMP response elements of the Id1 promoter (BRE-Luc). Activity of this promoter was 
induced by BMP-4 treatment of vector-control HepG2 cells. However, BMP-4-induced 
activation of the promoter was blocked when DLX4 was expressed (Figure 26C). 
Because TGF-β- and BMP-specific R-Smads utilize Smad4 as the common and 
essential partner for the formation of functional transcriptional complexes (201), our 
findings raise the possibility that DLX4 inhibits Smad4.  
 80 
 
 
Figure 26. Effect of DLX4 on TGF-β and BMP-induced transcription 
[A] HepG2 cells were co-transfected with empty vector (grey bar) or DLX4 (black bar) 
together with SBE-driven pSBE4-Luc reporter plasmid, and then cultured without and 
with TGF-β (10ng/ml) or BMP-4 (80 ng/ml) for 18 hours. [B] HepG2 cells were co-
transfected with empty vector (grey bar) or DLX4 (black bar), together with reporter 
plasmids containing no promoter (pGL2 vector) or a 1.6 kb region of the Id1 promoter. 
At 24 hours after transfection, cells were cultured without and with BMP-4 (80 ng/ml) 
for additional 18 hours. [C] HepG2 cells were co-transfected with empty vector (grey 
bar) or DLX4 (black bar) together with BRE-Luc reporter plasmid, and then cultured 
without and with BMP-4 (80 ng/ml) for 18 hours. Shown are relative F-Luc activities in 
three independent experiments each performed in duplicate and normalized by activity 
of co-transfected R-Luc.  
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3. DLX4 prevents Smad4 from binding R-Smads  
 
The formation of R-Smad/Smad4 transcriptional complexes is essential for 
Smad-mediated transcription (10, 12). In subsequent experiments, we determined 
whether DLX4 interferes with the binding of Smad4 to R-Smads. Following transfection 
with FLAG-tagged DLX4 or empty vector, HepG2 cells were treated with or without 
TGF-β. Smad2 was immunoprecipitated, and precipitates were analyzed by 
immunoblotting using Ab to Smad4. Binding of Smad4 to Smad2 was observed 
following TGF-β treatment. However, this interaction was inhibited when DLX4 was 
expressed (Figure 27A). Identical results were obtained in reciprocal 
immunoprecipitation (IP) assays in which Smad4 was immunoprecipitated and Smad2 
was detected in precipitates (Figure 27A).  
 
Because Smad2 and Smad3 are highly homologous and they both interact with 
Smad4 via their MH2 domains (8, 203), we determined whether DLX4 also interferes 
with interaction of Smad3 and Smad4. As shown in Figure 27A, treatment of vector-
control HepG2 cells with TGF-β induced binding of Smad4 to Smad3. In contrast, this 
binding was inhibited when DLX4 was expressed. DLX4 did not alter expression levels 
of Smad2, Smad3 or Smad4 (Figure 27B). Together, these results indicate that DLX4 
likely inhibits transcriptional activity of Smad2 and Smad3 by preventing Smad4 from 
interacting with these R-Smads.  
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Figure 27. DLX4 prevents Smad4 from binding R-Smads 
HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24 
hours thereafter, cells were serum-starved overnight and then treated without and with 
TGF-β (10ng/ml) for 30 minutes. [A] Smad2 was immunoprecipitated from nuclear 
extracts and precipitates were analyzed by immunoblotting using Ab to Smad4. 
Conversely, Smad4 was pulled-down and precipitates analyzed by immunoblotting 
using Smad2 Ab. Because HepG2 cells express low levels of Smad3, IP assays to 
detect binding of Smad3 to Smad4 were performed using extracts of cells that had 
been transfected with Smad3. [B] Western blot of DLX4 and Smad proteins in nuclear 
extracts.  
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4. DLX4 interacts with Smad4  
 
Our findings that DLX4 prevents Smad4 from interacting with R-Smads raise 
the possibility that DLX4 binds Smad4. In subsequent experiments, we determined 
whether DLX4 interacts with Smad4 and whether this interaction involves direct 
binding. 
 
4.1. DLX4 directly binds Smad4  
 
To initially investigate whether DLX4 associates with Smad4 in cells, IP assays 
were performed using extracts of HepG2 cells that expressed FLAG-DLX4 or empty 
vector. We found that FLAG-tagged DLX4 associated with Smad4, irrespective of 
TGF-β stimulation (Figure 28A). We next determined whether endogenous DLX4 could 
interact with Smad4. Endogenous DLX4 was immunoprecipitated by DLX4 Ab from 
lysates of MCF-7 cells, and Smad4 was detected in precipitates. IP of normal IgG was 
included as a negative control (Figure 28B). To additionally confirm the interaction of 
DLX4 with Smad4, we performed IP using extracts of MCF-7 cells that had been 
transfected with DLX4 shRNA (sh90) or with non-targeting shRNA. As shown in Figure 
28B, the interaction of DLX4 with Smad4 was reduced when DLX4 was knocked- 
down.  To determine whether DLX4 interacts with Smad4 by direct binding, we tested 
the ability of in vitro-translated 35S-labeled DLX4 to bind GST-Smad4 protein. GST-
pulldown assays demonstrated that DLX4 directly binds Smad4 (Figure 28C). DLX4 
also bound Smad2, but this binding was weaker than binding to Smad4 (Figure 28C).  
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Figure 28. DLX4 binds to Smad4 
[A] HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24 
hours thereafter, cells were serum-starved overnight and then treated without and with 
TGF-β (10ng/ml) for 30 min. FLAG-DLX4 was immunoprecipitated using FLAG Ab, 
and precipitates analyzed by immunoblotting using Ab to Smad4. Conversely, FLAG-
DLX4 was detected in precipitates following IP using Smad4 Ab. [B] MCF-7 cells were 
transfected with non-targeting shRNA or with DLX4 (sh90) shRNA. Endogenous DLX4 
was immunoprecipitated using DLX4 Ab, and precipitates analyzed by immunoblotting 
using Smad4 Ab. IP using mouse IgG was included as a negative control. [C] 
Expression of GST-Smad2 and GST-Smad4 proteins was confirmed by SDS-PAGE 
(left). GST-fusion proteins were assayed for direct binding to in vitro translated 35S-
labeled full-length DLX4 (right). 
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4.2. Identification of binding domains of DLX4 and Smad4 
 
We sought to identify the Smad4-binding domain of DLX4 by testing truncated 
GST-DLX4 fusion proteins for their ability to bind in vitro-translated 35S-labeled full-
length Smad4 (Figure 29A). We generated GST-DLX4 fusion proteins that contained 
full-length DLX4 (FL), only the homeodomain (HD), only the transactivation domain 
(TA), and the transactivation domain and homeodomain but lacking the C-terminal tail 
(TA+HD) (Figure 29B). Deletion of the C-terminal tail of DLX4 (TA+HD) only weakly 
affected its ability to bind Smad4 (Figure 29C). In contrast, deletion of the DNA-binding 
homeodomain of DLX4 markedly inhibited its Smad4-binding ability (TA). Binding of 
the DLX4 homeodomain to Smad4 (HD) was detected but not as strongly as observed 
with full-length DLX4 (Figure 29C).  
 
We also investigated which domain of Smad4 interacts with DLX4 by testing the 
ability of GST-DLX4 protein to bind in vitro-translated portions of Smad4 protein 
(Figure 30A). We generated in vitro-translated proteins that contained full-length 
Smad4 (FL), only the MH1 domain (MH1), only the MH2 domain (MH2), and the MH1 
and MH2 domains with the linker region (MH1+LK, LK+MH2) (Figure 30A). Direct 
binding of DLX4 was detected to the Smad4 MH1 domain alone, but not to the MH2 
domain (Figure 30C).  
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Figure 29. DLX4  binds to Smad4 in part via the homeodomain 
[A] GST-DLX4 constructs comprising the transactivation domain (TA), homeodomain 
(HD) and C-terminal tail (C). [B] Full-length (FL) DLX4 and portions thereof were 
expressed as GST-fusion proteins, and [C] assayed for binding to 35S-labeled full-
length Smad4. 
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Figure 30. DLX4 binds to the MH1 domain of Smad4 
[A] Smad4 constructs comprising MH1 and MH2 domains and linker (LK) region. [B] 
35S-labeled full-length and truncated Smad4 were translated in vitro and [C] assayed 
for binding to full-length GST-DLX4 protein. 
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5. DLX4 blocks interaction of Smad proteins with DNA 
 
Smad proteins bind to SBEs via their MH1 domains (33). Because DLX4 binds 
to the MH1 domain of Smad4, we investigated whether DLX4 blocks the interaction of 
Smad proteins to DNA. This was initially investigated by in vitro DNA pull-down 
assays. A biotinylated oligonucleotide containing sequences of the minimal p15Ink4B 
promoter region (nucleotides -108 to -39), including the SBEs (Figure 31A), was used 
to pull-down Smad proteins from nuclear extracts. Increased levels of Smad2 and 
Smad4 were detected in DNA-protein complexes when vector-control HepG2 cells 
were stimulated with TGF-β (Figure 31B). In contrast, these increased levels of Smad 
interactions with DNA were not observed when DLX4 was expressed (Figure 31B).  
 
To confirm the ability of DLX4 to block Smad-DNA interactions in a more 
physiological context, we performed ChIP assays. As shown in Figure 31C, 
association of Smad4 and R-Smads with the p15Ink4B promoter was detected by ChIP 
assays in vector-control HepG2 cells following TGF-β treatment. In contrast, 
interactions of Smad proteins with the p15Ink4B promoter were abrogated when DLX4 
was expressed (Figure 31C). 
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Figure 31. DLX4 blocks interactions of Smad proteins with the p15Ink4B promoter 
[A] Sequence of the minimal p15Ink4B promoter indicating Sp1 binding sites and SBEs 
(adapted from (51)). Underlined are sequences contained in the oligonucleotides used 
for oligonucleotide pull-down assays (solid line) and gel-shift assays (dashed line).   
[B] Biotinylated oligonucleotide containing sequences -108 to -39 of the p15Ink4B 
promoter was incubated with HepG2 nuclear extracts and pulled-down. DNA-bound 
proteins in precipitates were analyzed by immunoblotting. [C] ChIP analysis of 
interactions of Smad and Sp1 proteins with the p15Ink4B promoter. The input fraction 
corresponded to 1 % of the chromatin solution of each sample before IP.  
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C. CONCLUSION 
 
The studies in this chapter provide significant insight into the mechanism by 
which DLX4 blocks TGF-β/Smad signaling. Firstly, we demonstrate that DLX4 does 
not alter phosphorylation, expression and nuclear localization of Smad proteins but 
that DLX4 blocks TGF-β-induced transcriptional activity of Smad2 and Smad3. Our 
observation that DLX4 prevents Smad4 from binding to R-Smads suggests that DLX4 
inhibits the formation of R-Smad/Smad4 transcriptional complexes. We also 
demonstrate that DLX4 directly binds to the MH1 domain of Smad4, and that binding 
of DLX4 to Smad4 is mediated in part via its homeodomain.  Direct binding of DLX4 to 
Smad4 and the ability of DLX4 to also block BMP-induced transcription suggests that 
DLX4 could block signaling induced by different ligands of the TGF super-family that 
all utilize Smad4. In addition to the binding of Smad transcriptional complexes to 
SBEs, the interaction of Smad proteins with other transcription factors dictates the 
specificity and affinity of Smad complexes for target gene promoters. Understanding 
the interactions of Smads with other transcription factors will be the focus of Chapter 5.  
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CHAPTER 5: DLX4 REPRESSES SMAD/SP1-MEDIATED TRANSCRIPTION 
 
 
A. RATIONALE 
 
Both the strength and specificity of Smad-mediated transcription are governed 
by interactions of Smad complexes with specific transcriptional factors and their 
interactions with corresponding DNA-binding elements on target promoters (8, 10, 35) 
(Figures 4, 5). Transcriptional activation of genes encoding the CDK inhibitors p15Ink4B 
and p21WAF1/Cip1 is mediated by cooperative interactions between Sp1 and Smads that 
bind to GC boxes and SBEs respectively on the p15Ink4B and p21WAF1/Cip1 promoters 
(36, 38, 51).  
 
In Chapters 3 and 4, we determined that DLX4 blocks Smad-mediated induction 
of p15Ink4B and p21WAF1/Cip1. We found that DLX4 binds to Smad4, and blocks the 
interaction of Smad4 with R-Smads, and also the interactions of Smad complexes with 
DNA. Because cooperative interactions between Sp1 and Smads are important for 
Smad-mediated transcription of the CDK inhibitor genes, we hypothesize that DLX4 
could interfere with Smad-Sp1 interactions. The goal of the studies in this chapter is to 
determine whether and how DLX4 modulates Smad-Sp1-mediated transcription.   
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B. RESULTS 
 
1. DLX4 does not prevent interactions of Smad4 and Sp1 proteins 
 
TGF-β-induced transcription of p15Ink4B and p21WAF1/Cip1 requires cooperative 
interactions between Sp1 and Smads proteins, in particular, Smad4, (37, 38, 51). In 
initial experiments, we investigated whether DLX4 interferes with the interaction of 
Smad4 with Sp1 by IP assays. Following transfection with FLAG-tagged DLX4 or 
empty vector, HepG2 cells were treated with or without TGF-β. Sp1 was 
immunoprecipitated, and precipitates were analyzed by immunoblotting using Ab to 
Smad4. As reported in other studies (51), we similarly observed binding of Smad4 to 
Sp1 following TGF-β treatment of vector-control cells. Surprisingly, we observed 
interaction of Smad4 with Sp1 in cells that expressed DLX4, even in the absence of 
TGF-β stimulation (Figure 32A). These observations were confirmed in reciprocal IP 
assays in which Smad4 was immunoprecipitated and Sp1 was assayed in precipitates 
(Figure 32A). DLX4 did not alter the expression levels of Sp1 and Smad4 (Figure 
32B). This finding indicates that DLX4 facilitates interaction between Smad4 and Sp1 
independently of TGF-β stimulation. 
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Figure 32. DLX4 facilitates interactions of Smad4 and Sp1 
HepG2 cells were transfected with empty vector or with FLAG-tagged DLX4. At 24 
hours thereafter, cells were serum-starved overnight and then treated without and with 
TGF-β (10 ng/ml) for 30 minutes. [A] Sp1 was immunoprecipitated from nuclear 
extracts and precipitates analyzed by immunoblotting using Ab to Smad4. Conversely, 
Smad4 was pulled-down and precipitates analyzed by immunoblotting using Sp1 Ab.  
[B] Western blot of DLX4 and Smad4 and Sp1 in nuclear extracts.  
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2. DLX4 interacts with Sp1 
 
In Smad/Sp1 transcriptional complexes, Sp1 directly binds Smad4 (51). 
Because we previously found that DLX4 directly binds Smad4, it is possible that DLX4 
also interacts with Sp1. In subsequent experiments, we determined i) whether DLX4 
interacts with Sp1, ii) whether this interaction involves direct binding, and iii) what are 
the binding domains of Sp1 and DLX4. 
 
2.1. DLX4 directly binds Sp1 
 
We first determined whether DLX4 interacts with Sp1 in cells. IP assays were 
performed using extracts of HepG2 cells that expressed FLAG-DLX4 or empty vector. 
FLAG-tagged DLX4 associated with Sp1, irrespective of TGF-β stimulation (Figure 
33A). We next determined whether endogenous DLX4 interacts with Sp1. Endogenous 
DLX4 was immunoprecipitated by DLX4 Ab from lysates of MCF-7 cells, and Sp1 was 
detected in precipitates. IP of normal IgG was included as a negative control (Figure 
33B). To confirm the interaction of DLX4 with Sp1, we performed IP using lysates of 
MCF-7 cells that had been transfected with DLX4 shRNA (sh90) or with non-targeting 
shRNA. As shown in Figure 33B, the interaction of DLX4 with Sp1 was reduced when 
DLX4 was knocked-down. 
 
To determine whether DLX4 directly binds Sp1, we performed GST-pulldown 
assays. Full-length GST-DLX4 fusion protein (FL) directly bound to in vitro-translated     
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Figure 33. DLX4 associates with Sp1 
[A] Lysates were prepared from HepG2 cells as described in Figure 32A. Interaction of 
FLAG-DLX4 with Sp1 was detected by reciprocal IP using FLAG and Sp1 Abs. [B] 
MCF-7 cells were transfected with non-targeting shRNA or with DLX4 (sh90) shRNA. 
Endogenous DLX4 was immunoprecipitated using DLX4 Ab, and precipitates analyzed 
by immunoblotting using Sp1 Ab. IP using mouse IgG was included as a negative 
control. 
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35S-labeled full-length Sp1 (Figure 34A). Similarly, full-length GST-Sp1 fusion protein 
was observed to bind in vitro-translated 35S-labeled DLX4 (Figure 34C).  
 
2.2. Identification of binding domains of DLX4 and Sp1 
 
We determined the domain of DLX4 that binds to Sp1 by performing GST pull-
down assays using GST-DLX4 fusion proteins that contained different domains of 
DLX4 (Figure 29A, B). Binding of the homeodomain of DLX4 to in vitro-translated Sp1 
was strongly detected (Figure 34A). This binding was comparable to binding of full-
length DLX4 to Sp1. Deletion of the C-terminal tail or the transactivation domain of 
DLX4 did not affect its ability to bind Sp1 (Figure 34A).  
 
In converse experiments, we determined the domain of Sp1 that binds DLX4. 
Sp1 comprises a C-terminal DNA-binding domain [amino acids 557 to 778] and an N-
terminal transactivation domain [amino acids 1 to 557] (Figure 34B). We generated in 
vitro-translated 35S-labeled proteins that contained full-length Sp1 (FL), the DNA-
binding domain of Sp1 (DBD) and its transactivation domain (TA) (Figure 34C). DLX4 
did not bind the transactivation domain of Sp1, but bound to its DNA-binding domain 
(Figure 34C). Together, these findings demonstrate that the interaction between DLX4 
and Sp1 is mediated via their respective DNA-binding domains. 
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Figure 34. DLX4 binds to the DNA-binding domain of Sp1 
[A] GST-DLX4 proteins (described in Figure 29A) were assayed for binding to 35S-
labeled full-length Sp1. [B] Sp1 constructs comprising the transactivation domain (TA) 
and DNA-binding domain (DBD). [C] 35S-labeled full-length (FL) and truncated Sp1 
were translated in vitro (left) and assayed for binding to full-length GST-DLX4 protein 
(right). 
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3. DLX4 inhibits DNA-binding activity of Sp1 
 
3.1. DLX4 blocks interactions of Sp1 with the p15Ink4B promoter 
 
Because DLX4 binds the DNA-binding domain of Sp1, it is possible that DLX4 
interferes with the DNA-binding ability of Sp1. To determine whether DLX4 alters the 
binding of Sp1 to its recognition element, we performed in vitro DNA pull-down assays 
using a biotinylated oligonucleotide containing sequences of the minimal p15Ink4B 
promoter region (nucleotides -108 to -39). This contains two GC boxes plus two SBEs 
(Figure 35A). In contrast to Smad proteins, binding of Sp1 to this promoter was 
detected in lysates of vector-control HepG2 cells in the absence of TGF-β stimulation 
(Figure 35B).  TGF-β stimulation increased the level of DNA-bound Sp1 in vector-
control cells (Figure 35B). However, very little DNA-bound Sp1 was detected in lysates 
of HepG2 cells that expressed DLX4, irrespective of TGF-β stimulation (Figure 35B).  
 
To confirm this finding in a more physiological context, ChIP was performed to 
assay binding of endogenous Sp1 to the p15Ink4B promoter. As shown in Figure 35C, 
association of Sp1 with the p15Ink4B promoter was detected in vector-control HepG2 
cells following TGF-β treatment. In contrast, binding of Sp1 to the p15Ink4B promoter 
was not detected in cells that expressed DLX4, irrespective of TGF-β stimulation 
(Figure 35C). The ability of DLX4 to block binding of Sp1 to the p15Ink4B promoter is 
similar to its ability to block DNA-binding of Smad proteins as we demonstrated in 
Chapter 4. Together, these findings indicate that DLX4 blocks the interaction of 
Smad/Sp1 complexes with target gene promoters.  
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Figure 35. DLX4 blocks interactions of Sp1 protein with the p15Ink4B promoter 
[A] Sequence of the minimal p15Ink4B promoter indicating Sp1 binding sites and SBEs 
(adapted from (51)). Underlined are sequences contained in the oligonucleotides used 
for oligonucleotide pull-down assays (solid line) and gel-shift assays (dashed line). [B] 
Biotinylated oligonucleotide containing sequences -108 to -39 of the p15Ink4B promoter 
was incubated with HepG2 nuclear extracts and pulled-down. DNA-bound proteins in 
precipitates were analyzed by immunoblotting. [C] ChIP analysis of interactions of Sp1 
with the p15Ink4B promoter. The input fraction corresponded to 1 % of the chromatin 
solution of each sample before IP.    
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3.2. DLX4 blocks the DNA-binding ability of Sp1, independently of Smad proteins 
 
In subsequent experiments, we sought to determine whether DLX4 blocks the 
DNA-binding ability of Sp1, independently of Smad proteins. Gel-shift assays were 
performed to test the ability of DLX4 to prevent Sp1 from binding sequences of the 
minimal p15Ink4B promoter region (nucleotides -88 to -63). Addition of increasing 
amounts of recombinant FLAG-tagged DLX4 blocked the binding of recombinant Sp1 
to the DNA probe (Figure 36A). In contrast, addition of increasing amounts of FLAG-
tag alone did not affect the DNA-binding ability of Sp1 (Figure 36A). 
 
Because DLX4 blocks DNA-binding ability of Sp1, we also investigated whether 
DLX4 blocks Sp1-induced transcription, independently of Smads. We performed 
reporter assays using a synthetic promoter that comprised tandem Sp1-binding sites 
(Figure 36B). Enforced expression of DLX4 in Smad4-deficient MDA-MB-468 cells 
inhibited activity of the Sp1-driven promoter (Figure 36B). Conversely, knock-down of 
DLX4 in MCF-7 cells stimulated Sp1-driven promoter activity (Figure 36B).  
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Figure 36. DLX4 blocks DNA-binding ability of Sp1 
[A] Gel shift analysis using a 32P-labeled oligonucleotide containing nucleotides -88 to 
-64 of the p15Ink4B promoter (refer figure 35A). Recombinant Sp1 protein was 
incubated with increasing amounts of in vitro translated FLAG-DLX4 and FLAG-tag. 
Gel-shifted DNA-bound Sp1 is indicated. [B] MDA-MB-468 cells were co-transfected 
with empty vector (-DLX4) or DLX4, together with the Cignal Sp1 reporter construct 
driven by a synthetic promoter comprising tandem Sp1-binding sites (left). Sp1-driven 
promoter activity was, likewise, assayed in MCF-7 cells that were co-transfected with 
non-targeting shRNA or DLX4 (sh90) shRNA (right). Shown are average relative F-Luc 
activities in three independent experiments each performed in duplicate. Values were 
normalized by activity of co-transfected R-Luc. 
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C. CONCLUSION 
 
Cooperative interactions between Smad proteins and Sp1 are important for 
TGF-β-induced transcription of CDK inhibitor genes. In this chapter, we identified the 
mechanism of how DLX4 blocks Smad/Sp1-mediated transcription. We found that 
DLX4 does not prevent the interaction between Sp1 and Smad4, but blocks the 
interactions of Sp1 and Smad proteins with the p15Ink4B promoter. We also 
demonstrate that DLX4 directly binds to the DNA-binding domain of Sp1, and inhibits 
the DNA-binding ability of Sp1. Together, these results indicate that DLX4 inhibits 
Smad/Sp1-mediated transcription by inhibiting the DNA-binding ability of Sp1, in 
addition to preventing Smad4 from interacting with R-Smads as identified in Chapter 4.  
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CHAPTER 6: DISCUSSION 
 
 
A. DLX4 COUNTERACTS KEY TRANSCRIPTIONAL CONTROL MECHANISMS OF 
THE TGF-β CYTOSTATIC PROGRAM 
 
The TGF-β cytostatic program is essential for maintaining normal tissue 
homeostasis. Gene responses that are central to the TGF-β cytostatic program include 
induction of the CDK inhibitors p15Ink4B and p21WAF1/Cip1 and repression of c-myc. 
These gene responses are tightly regulated by a repertoire of transcriptional regulators 
that include Smad proteins, Sp1 and c-myc (3, 4). My studies in Chapter 3 (Aim 1) 
demonstrate that DLX4, a homeodomain protein that is expressed in many types of 
cancers, blocks the anti-proliferative effect of TGF-β by preventing G1 arrest. DLX4 
inhibits TGF-β-induced expression of p15Ink4B and p21WAF1/Cip1 and blocks TGF-β-
mediated repression of c-myc expression. In addition, my studies demonstrate that 
DLX4 induces c-myc expression independently of TGF-β signaling. My studies in 
Chapter 4 (Aim 2) and Chapter 5 (Aim 3) identify and characterize several distinct 
mechanisms by which DLX4 inactivates transcriptional control of the TGF-β cytostatic 
program.  
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1. DLX4 sequesters Smad4 and prevents Smad4 from binding R-Smads  
 
The formation of transcriptional complexes of Smad4 and activated R-Smads 
upon TGF-β stimulation is essential for Smad-mediated transcription (10, 12). My 
studies indicate that DLX4 does not alter Smad phosphorylation, expression or nuclear 
translocation (Figure 22). However, my studies identify that DLX4 blocks Smad 
transcriptional activity (Figures 24 and 25) by directly binding to Smad4 and preventing 
Smad4 from binding to R-Smads (Figures 27 and 28). Smad interactions might also be 
prevented by the binding of DLX4 to R-Smads, as we observed that DLX4 directly 
binds to Smad2 (Figure 28). However, binding of DLX4 to Smad2 was much weaker 
than to Smad4. Because Smad4 and R-Smads interact with one another via their MH2 
domains (201), our finding that DLX4 binds the Smad4 MH1 domain is somewhat 
surprising. One explanation could be that binding of DLX4 to the Smad4 MH1 domain 
induces a conformational change such that the MH2 domain of Smad4 is unable to 
interact with R-Smads (Figure 37). One way to test this would be to perform X-ray 
crystallography studies of DLX4 interactions with Smad proteins. However, since 
Smad proteins bind DNA via their MH1 domains, the binding of DLX4 to the MH1 
domain is consistent with the observed ability of DLX4 to block the ability of Smads to 
bind DNA (Figure 31). Smad proteins have been reported to interact with a variety of 
other transcription factors (reviewed in (203)). However, most of these other 
transcription factors interact with the MH2 domain of Smad proteins, and very few 
interact with the MH1 domain.  
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Figure 37. Predicted model of DLX4, Smad4 and Sp1 interactions 
In the absence of TGF-β stimulation, Sp1 binds to the GC box element on target gene 
promoters to drive basal transcription [A]. Upon TGF-β stimulation, R-Smads and 
Smad4 form transcriptional complexes with Sp1 and induce gene transcription [B]. In 
cells that highly express DLX4, DLX4 forms an inactive complex in the nucleus by 
directly binding to both Sp1 and Smad4 and represses gene transcription [C]. TGF-β 
stimulation activates R-Smads and induces their translocation into the nucleus. 
However, activated R-Smads fail to bind to Smad4 due to the blocking effect of DLX4. 
As a consequence, TGF-β cannot induce transcription of target genes [D]. 
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2. Interaction of DLX4 and Sp1 
 
Binding affinity and selectivity of Smad complexes for target gene promoters are 
principally dictated by interactions of Smads with other DNA-binding factors (10, 201). 
Similarly, binding affinity and selectivity of several homeodomain proteins are 
modulated by interactions with other transcriptional regulators (204, 205). Sp1 is an 
important binding partner of Smad proteins that cooperates with Smads to induce 
transcription of p15Ink4B and p21WAF1/Cip1. Upon TGF-β stimulation, Sp1 binds to MH1 
domain of Smad4 and the MH2 domain of Smad2 to form Sp1/Smad complexes that 
bind to the promoters via their respective binding sites (37, 51).  Surprisingly, we 
observed that DLX4 does not prevent Sp1 from associating with Smad4 in TGF-β-
stimulated cells (Figure 32A). Notably, DLX4 seemed to facilitate Smad4-Sp1 
interactions even in the absence of TGF-β stimulation (Figure 32A). Furthermore, my 
studies demonstrate that DLX4 directly binds the DNA-binding domain of Sp1 and 
impairs the DNA-binding ability of Sp1 (Figures 34, 35 and 36). This study is the first to 
demonstrate that a homeodomain protein directly interacts with Sp1 and modulates 
Sp1 activity. Since my studies demonstrated that DLX4 directly binds to Smad4 and to 
Sp1, we speculate that DLX4 inhibits p15Ink4B transcription by two integrated 
mechanisms. Firstly, DLX4 might recruit Sp1 and Smad4 to form a transcriptionally 
inactive DLX4-Smad-Sp1 complex that is unable to bind TGF-β-activated R-Smads. 
Secondly, by directly binding to the DNA-binding domains of Smad4 and of Sp1, DLX4 
might dislodge Smad4 and Sp1 from the p15Ink4B promoter (Figure 37). Because 
transcription of p21WAF1/Cip1 is also induced by TGF-β via cooperative interactions 
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between Sp1 and Smad proteins (38), DLX4 might inhibit p21WAF1/Cip1 transcription by 
a similar mechanism. 
 
3. Induction of c-myc by DLX4 
 
My studies indicate that DLX4 induces expression of c-myc by two 
mechanisms. On one hand, DLX4 can block the ability of TGF-β to repress c-myc 
promoter activity (Figure 20). As previously discussed in Chapter 1, interaction of the 
repressive complex comprising Smad3, Smad4 and E2F4/5, DP1 and p107 with the 
TIE element in the c-myc promoter blocks c-myc transcription (46, 47) (Figure 5A). 
Because DLX4 blocks Smad4 from binding activated Smad3 (Figure 27A), DLX4 might 
block formation of the repressive complex and thereby derepress the c-myc promoter. 
My studies also demonstrate that DLX4 induces c-myc expression independently of 
TGF-β/Smad signaling. One possibility is that DLX4 directly activates the c-myc 
promoter. The c-myc promoter contains multiple TAAT core motifs that are recognized 
by homeodomain proteins. Indeed, it has been reported that another homeodomain 
protein, HOXB4, induces c-myc promoter activity (206).  
 
Our finding that DLX4 induces expression of c-myc independently of TGF-β 
signaling has several implications. Firstly, induction of c-myc by DLX4 provides a 
competing mitogenic signal against the TGF-β cytostatic program. c-myc induces 
expression of numerous cell cycle facilitators such as Id2, cdc25A and cyclin D1 (57, 
58, 207, 208). Secondly, DLX4-induced c-myc expression might lead to down-
regulated expression of p15Ink4B and p21WAF1/Cip1, because transcription of these genes 
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is repressed by c-myc (62, 63). The repression of p15Ink4B transcription by c-myc has 
some similarity to our observations with DLX4. We found that interaction of Sp1 with 
Smad4 was not disrupted by DLX4. Feng et al., likewise, reported that c-myc does not 
compete with Sp1 for interaction with Smads (62). These authors speculated that by 
interacting with activated Smad2/3, c-myc promotes the formation of an inactive 
transcription complex with Smad proteins and Sp1. However, there are notable 
differences in the mechanisms by which DLX4 and c-myc repress p15Ink4B promoter 
activity. In my studies, DLX4 was found to inhibit interactions between Smad4 and R-
Smads, and to inhibit R-Smad transcriptional activity. In contrast, c-myc does not 
inhibit interactions between Smad4 and R-Smads (62). Furthermore, in my studies, 
DLX4 was found to inhibit DNA-binding activity of Sp1. In contrast, c-myc does not 
affect binding of Sp1 to the p15Ink4B promoter (62). DLX4 might, therefore, repress 
p15Ink4B and possibly also p21WAF1/Cip1 transcription by three distinct, but integrated, 
mechanisms: i) by increasing c-myc expression, ii) by preventing Smad4 from binding 
R-Smads, and iii) by blocking Sp1 DNA-binding activity.  
 
B. INTERACTIONS BETWEEN DLX GENES AND THE TGF SUPER-FAMILY 
 
1. Cross-regulation of DLX genes and TGF super-family members 
 
The ability of DLX4 to block TGF-β signaling might be related to the functions of 
DLX genes in controlling bone morphogenesis and skeletal patterning (1, 129). These 
processes are tightly regulated by members of the TGF super-family. Because DLX4 
binds Smad4, DLX4 also likely blocks signaling emanating from other receptors of the 
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TGF super-family. Indeed, we found that DLX4 inhibited induction of transcriptional 
activity by BMP-4 (Figure 26). DLX1 has been reported to inhibit activin signaling 
(184). Conversely, signaling by TGF super-family members can modulate expression 
or activity of DLX proteins. For example, BMP-2 activates DLX3 transcription (182). 
Smad6, an antagonist of BMP signaling, inhibits DLX3 transcriptional activity (183). 
Interestingly, we observed that levels of DLX4 protein decreased in cells following 
TGF-β stimulation (Figure 18). DLX4 might be a component of a regulatory loop that 
blocks TGF-β signaling and is conversely regulated by TGF-β. This feedback 
mechanism might play an important role in controlling normal embryogenesis and 
homeostasis.  
 
2. Binding specificity of homeodomain proteins to Smads 
 
Transcription factors encoded by homeobox genes are characterized by their 
conserved helix-turn-helix DNA-binding homeodomain (209). Our findings that binding 
of DLX4 to the MH1 domain of Smad4 is mediated in part through the homeodomain 
of DLX4 raises the question of specificity. Transcription factors encoded by various 
homeobox genes have been reported to bind Smads, but not all of these interactions 
are solely mediated via the homeodomain. For example, proteins encoded by the 
Mixer and Milk homeobox genes bind Smad2 through a region distinct from their 
homeodomains (181). DLX1 has been reported to bind Smad4, but its binding region 
has not been identified (184). Transcription factors encoded by various other 
homeobox genes have been reported to bind Smads via their homeodomain. 
However, the specificity of homeodomain proteins for different Smads is striking. Most 
 112 
 
 
of the interactions between homeodomain proteins and Smads reported so far are with 
either R-Smads or I-Smads. DLX3 binds Smad6 but not Smad4 (183). HOXA13 binds 
Smad1, Smad2 and Smad5 but does not bind Smad4 (185). Furthermore, different 
homeodomain proteins bind different domains of Smad proteins. For example, HOXC8 
interacts with the MH1 domain of Smad1 (210), whereas HOXA13 binds the MH2 
domains of Smad1 (185). Within the homeodomain, the residues of the third helix are 
the most highly conserved (127). Less conserved residues of the first and second 
helices might govern preferential binding to a specific Smad protein or Smad domain.  
My study is the first to demonstrate a direct interaction of a homeodomain protein to 
the MH1 domain of Smad4. Indeed, very few transcription factors are known to bind 
the MH1 domain of Smad4 (reviewed in (203)). However, it is possible that other 
homeodomain proteins could bind Smad4 and potentially block TGF-β-mediated 
growth inhibition by a mechanism similar to that of DLX4. Nonetheless, the specificity 
of this inhibition could largely depend on the context of the expression of homeobox 
genes. Most homeobox genes are expressed in a highly tissue-specific manner (137, 
209). In contrast, DLX4 is expressed across diverse malignancies (Table 5). No other 
homeobox gene has been reported to be commonly expressed in tumors of lung, 
breast, ovary, prostate and hematologic origin. Interference of TGF-β-mediated growth 
inhibition by DLX4 could, therefore, be a mechanism common to multiple organ sites. 
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C. THE ROLE OF HOMEOBOX GENE DLX4 IN TUMORIGENESIS  
 
1. Resistance of tumors to the anti-proliferative effect of TGF-β  
 
Resistance to TGF-β-mediated growth-inhibition is an important feature in the 
pathogenesis of most types of tumors (3, 4, 95). This resistance has been attributed to 
TGF-β receptor or Smad mutations in several types of tumors, particularly those of 
gastrointestinal and pancreatic origin (Table 2). Resistance of tumor cells to the anti-
proliferative effect of TGF-β can also stem from down-regulation of TGF-β receptor 
expression (211), activation of Smad repressors, repression of Smad activators 
(Figure 2) and mutation of downstream targets such as p15Ink4B deletion (212). The 
ability of DLX4 to block TGF-β-mediated growth inhibition could explain why tumors 
that lack aberrations in core components of the TGF-β signaling pathway can become 
resistant to the anti-proliferative effect of TGF-β. It would be important in future studies 
to determine whether DLX4 is aberrantly activated in tumors that have TGF-β receptor 
or Smad mutations, and what is the effect of DLX4 in these tumors. It is interesting to 
note that Ski and SnoN proteins also can block the anti-proliferative effect of TGF-β 
and that these proteins are both elevated in many types of cancer. The sno gene is 
also located in a chromosomal locus that is frequently amplified in many tumors 
(reviewed in (29)). However, the mechanisms for the blocking effect of Ski/Sno are 
distinct from that of DLX4. Ski/Sno blocks TGF-β/Smad signaling in a “gene non-
specific” manner by recruiting N-CoR/mSin3/HDAC repressor complexes to Smad4/R-
Smad transcription complexes (27-29). However, in this study, we demonstrated that 
DLX4 blocks TGF-β/Smad signaling by both “gene non-specific” and “gene specific” 
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mechanisms. As discussed earlier, DLX4 blocks TGF-β/Smad signaling by a “gene 
non-specific” mechanism via binding Smad4 and preventing binding of Smad4 to TGF-
β-activated R-Smads. DLX4 also blocks TGF-β-mediated induction of p15Ink4B and 
p21WAF1/Cip1 transcription by a “gene specific” mechanism via forming a transcriptionally 
inactive complex with Smad4 and Sp1, and by inducing expression of c-myc, a 
repressor of p15Ink4B and p21WAF1/Cip1 transcription.   
 
2. Other roles of DLX4 in tumor progression 
 
A striking aspect of the TGF-β signaling pathway in tumors is its biphasic 
function. Many tumors are resistant to the anti-proliferative effect of TGF-β but retain 
other TGF-β-mediated mechanisms that promote EMT and metastasis (3, 4). It has 
been thought that core components of the TGF-β pathway remain functional in these 
tumors, whereas downstream aberrations (such as p15Ink4B deletion) disable the 
growth-inhibitory arm of the pathway (3, 4). By sequestering Smad4, DLX4 inactivates 
the core pathway and might also block the metastasis-promoting function of TGF-β. 
Indeed, DLX4 markedly, but not completely, inhibited TGF-β-induced EMT in NMuMG 
cells (Figure 21). The ability of DLX4 to inhibit TGF-β-induced EMT could explain the 
association of DLX4 with favorable prognosis in lung cancer patients and its 
metastasis-suppressive activity reported by Tomida et al. (178). However, DLX4 levels 
in ovarian and breast cancers have been reported to correlate with disease 
progression (173, 176). There are several possible explanations for this paradox. As 
described in Chapter 1, TGF-β not only induces EMT by Smad-dependent 
mechanisms, but also via Smad-independent pathways that involve MAP kinase and 
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RhoA activation (88). TGF-β-induced, non-Smad pathways that promote cell migration 
might not be inhibited by DLX4. One way to test this possibility is to assay the effect of 
DLX4 on cell migration using MDA-MB-468 breast cancer cells that have homozygous 
deletion of Smad4. DLX4 could also promote tumor progression by other mechanisms 
such as sustained induction of c-myc. For example, c-myc not only stimulates cell 
growth but also promotes tumor metastasis (213). In addition, our laboratory has found 
that DLX4 promotes tumor angiogenesis by inducing expression of vascular 
endothelial growth factor and fibroblast growth factor-2 (FGF-2) (173). The mechanism 
that gives rise to overexpression of DLX4 in tumors is unclear. The DLX4 gene maps 
to the 17q21.3-q22 region, a chromosomal “hot-spot” that is amplified in ~10% of 
breast and ovarian cancers (175, 214). However, DLX4 overexpression occurs in 
>50% of these tumors (173, 176) indicating that gene amplification is not the sole 
mechanism underlying this overexpression. 
 
3. Functional significance of homeobox genes in cell growth deregulation in 
cancers 
 
In addition to the ability of DLX4 to block the TGF-β anti-growth signal identified 
in this study, other reports implicate a function for DLX4 in enhancing cell survival. The 
anti-apoptotic effect of DLX4 has been associated with its ability to induce expression 
of GATA-1 and bcl-2 (171, 190). DLX4 has also been reported to repress expression 
of the DNA-damage repair protein BRCA1 in breast cancer, suggesting that DLX4 
might play a role in DNA-damage repair (189). Aberrant expression of other homeobox 
genes can also promote tumor cell survival and growth. HOXA1 is overexpressed in 
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breast cancers and promotes tumor cell survival by inducing bcl-2 expression (215). 
HSIX1 is also highly expressed in breast cancers and causes abrogation of the G2 
checkpoint by inducing expression of cyclin A1 (162, 163). HOXB7 is overexpressed in 
melanomas, breast and ovarian cancers and induces expression of FGF-2 (167, 216). 
On the other hand, several homeobox genes can inhibit cell growth, and their 
expression is lost in tumors. CDX2 inhibits cell growth by inducing expression of 
p21WAF1/Cip1, and CDX2 is down-regulated in colon cancers (152, 217). p53 is a direct 
transcriptional target of HOXA5 (145). Loss of HOXA5 expression has been reported 
in >60% of breast cancers (145). My study is the first report that functionally links a 
homeobox gene that is aberrantly expressed in tumors with resistance to the cytostatic 
activity of TGF-β. This study significantly supports a growing body of evidence that 
aberrant expression of homeobox genes can deregulate tumor cell growth by a wide 
variety of different mechanisms. 
 
D. CONCLUSION  
 
Resistance to the anti-proliferative effect of TGF-β is an important feature in the 
pathogenesis of most types of cancers. Resistance of many tumors to TGF-β cannot 
be solely explained by TGF-β receptor and Smad mutations or deletions. My studies 
demonstrate that DLX4 blocks the anti-proliferative effect of TGF-β by disabling key 
transcriptional control mechanisms of the TGF-β cytostatic program. My studies also 
provide a molecular explanation as to why many tumors are resistant to the growth-
inhibitory effect of TGF-β in the absence of mutations in core components of the TGF-
β signaling pathway (Figure 38). Escape from anti-proliferative signals is an important 
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and early step in tumor pathogenesis. DLX4 might therefore, serve as a useful early 
detection marker and therapeutic target for multiple types of tumors.  At a broader 
level, my studies might provide insight into how aberrant activation of a developmental 
patterning gene promotes tumor pathogenesis. Conversely, the finding of this study 
that DLX4 modulates TGF-β signaling in tumors also provides insights into how 
homeobox genes and TGF-β signaling interact to control normal developmental 
patterning. 
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Figure 38. DLX4 blocks TGF-β-induced G1 arrest  
TGF-β induces G1 arrest primarily by inducing expression of CDK inhibitors, p15Ink4B 
and p21WAF1/Cip1. DLX4 prevents G1 arrest by blocking TGF-β/Smad signaling and by 
inducing expression of c-myc, a transcriptional repressor of p15Ink4B and p21WAF1/Cip1, 
independently of TGF-β signaling. 
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